ZMB Member Dirk Schadendorf

ZMB Member
Dirk Schadendorf

Next ZMB-Member
Dirk Schadendorf portrait
Martin Kaiser/UKE

Prof. Dr. Dirk Schadendorf

Director of:

Clinic for Dermatology

University Hospital Essen
Hufelandstraße 55
45147 Essen

Research Overview

  • Malignant melanoma
  • Merkel cell carcinoma
  • Squamous cell carcinoma
  • Basal cell carcinoma
  • Mycosis Fungoides/Sezary syndrome (T-Zell-Non-Hodgkin-Lymphoma)
  • Application observation

Read more

Selected Publications

    Journal articles

  • Long, Georgina V.; Garnett-Benson, Charlie; Dolfi, Sonia; Ascierto, Paolo A.; Guo, Jun; Tarhini, Ahmad A.; Chandra, Sunandana; Muñoz-Couselo, Eva; Del Vecchio, Michele; de Melo, Andreia Cristina; Callahan, Margaret; Gogas, Helen; Dummer, Reinhard; Schadendorf, Dirk; Koelblinger, Peter; Quereux, Gaelle; Thomas, Ioannis; Yu, Jia Xin; Fisher, Andrew; Wang, Bonnie; Djidel, Patrick; Chouzy, Armand; Semaan, Mark; Chen, Bohang; Cheong, Alicia M. Y.; Tawbi, Hussein A.
    Adjuvant nivolumab and relatlimab in stage III/IV melanoma : the randomized phase 3 RELATIVITY-098 trial
    In: Nature Medicine, 2025, in press
    DOI (Open Access)
  • Syeda, Mahrukh M; Long, Georgina V; Garrett, James; Atkinson, Victoria; Santinami, Mario; Schadendorf, Dirk; Hauschild, Axel; Millward, Michael; Mandala, Mario; Chiarion-Sileni, Vanna; Smylie, Michael; Manikhas, Georgy M; Dummer, Reinhard; Wiggins, Jennifer M; Ali, Saim; Adnaik, Sachin Bajirao; Tan, Monique; Dajee, Maya; Polsky, David
    Clinical validation of droplet digital PCR assays in detecting BRAFV⁶⁰⁰-mutant circulating tumour DNA as a prognostic biomarker in patients with resected stage III melanoma receiving adjuvant therapy (COMBI-AD) : A biomarker analysis from a double-blind, randomised phase 3 trial
    In: The Lancet Oncology, Vol. 26, 2025, Nr. 5, pp. 641 – 653
    DOI
  • Kolb, Antonia; Kulis-Mandic, Ana-Marija; Klein, Matthias; Stastny, Anna; Haist, Maximilian; Votteler, Vanessa; Weidenthaler-Barth, Beate; Sinnberg, Tobias; Sucker, Antje; Allies, Gabriele; Albrecht, Jessica Lea; Tasdogan, Alpaslan; Tuettenberg, Andrea; Gaida, Matthias M.; Deppermann, Carsten; Stege, Henner; Schadendorf, Dirk; Grabbe, Stephan; Schulze-Osthoff, Klaus; Kramer, Daniela
    Constitutive expression of the transcriptional co-activator IκBζ promotes melanoma growth and immunotherapy resistance
    In: Nature Communications, Vol. 16, 2025, Nr. 1, 5387
    DOI (Open Access)
  • Amaral, T.; Ottaviano, M.; Arance, A.; Blank, C.; Chiarion-Sileni, V.; Donia, M.; Dummer, R.; Garbe, C.; Gershenwald, J.E.; Gogas, H.; Guckenberger, M.; Haanen, J.; Hamid, O.; Hauschild, A.; Höller, C.; Lebbé, C.; Lee, R.J.; Long, G.V.; Lorigan, P.; Muñoz Couselo, E.; Nathan, P.; Robert, C.; Romano, E.; Schadendorf, Dirk; Sondak, V.; Suijkerbuijk, K.P.M.; van Akkooi, A.C.J.; Michelin, O.; Ascierto, P.A.; Michielin, O.
    Cutaneous melanoma : ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
    In: Annals of Oncology, Vol. 36, 2025, Nr. 1, pp. 10 – 30
    DOI
  • Haggenmüller, Sarah; Wies, Christoph; Abels, Julia; Winterstein, Jana T.; Heinlein, Lukas; Nogueira Garcia, Carina; Utikal, Jochen S.; Wohlfeil, Sebastian A.; Meier, Friedegund; Hobelsberger, Sarah; Gellrich, Frank F.; Sergon, Mildred; Hauschild, Axel; French, Lars E.; Heinzerling, Lucie; Schlager, Justin G.; Ghoreschi, Kamran; Schlaak, Max; Hilke, Franz J.; Poch, Gabriela; Korsing, Sören; Sarfert, Cosimo; Berking, Carola; Heppt, Markus V.; Erdmann, Michael; Haferkamp, Sebastian; Drexler, Konstantin; Schadendorf, Dirk; Sondermann, Wiebke; Goebeler, Matthias; Schilling, Bastian; Kather, Jakob Nikolas; Fröhling, Stefan; Llamas-Velasco, Mar; Requena, Luis C.; Ferrara, Gerardo; Fernandez-Figueras, Maite; Fraitag, Sylvie; Müller, Cornelia S. L.; Starz, Hans; Kutzner, Heinz; Barnhill, Raymond; Carr, Richard; Resnik, Kenneth S.; Braun, Stephan Alexander; Holland-Letz, Tim; Brinker, Titus J.
    Discordance, accuracy and reproducibility study of pathologists’ diagnosis of melanoma and melanocytic tumors
    In: Nature Communications, Vol. 16, 2025, Nr. 1, 789
    DOI (Open Access)
  • Kähler, K.C.; Hassel, J.C.; Ziemer, M.; Rutkowski, P.; Meier, F.; Flatz, L.; Gaudy-Marqueste, C.; Zimmer, Lisa; Santinami, M.; Russano, F.; von Wasielewski, I.; Eigentler, T.K.; Maio, M.; Zalaudek, I.; Haferkamp, S.; Quaglino, P.; Welzel, J.; Röcken, C.; Enk, A.; Simon, J.-C.; Świtaj, T.; Garzarolli, M.; Amaral, T.; Malissen, N.; Livingstone, Elisabeth; Elia, G.; Covelli, A.; Lorizzo, K.; Neri, D.; Mulatto, S.; Parca, A.; Pizzichi, B.; Ascierto, P.A.; Garbe, C.; Robert, C.; Schadendorf, Dirk; Hauschild, A.
    Neoadjuvant intralesional targeted immunocytokines (daromun) in stage III melanoma
    In: Annals of Oncology, Vol. 36, 2025, Nr. 10, pp. 1166 – 1177
    DOI (Open Access)
  • Hauschild, Axel; Garbe, Claus; Ascierto, Paolo Antonio; Demidov, Lev; Dreno, Brigitte; Dummer, Reinhard; Eggermont, Alexander; Forsea, Ana-Maria; Gebhardt, Christoffer; Gershenwald, Jeffrey E; Hamid, Omid; Hoeller, Christoph; Kandolf, Lidija; Kaufmann, Roland; Kirkwood, John M; Lebbé, Celeste; Long, Georgina V; Malvehy, Josep; Martin-Algarra, Salvador; McArthur, Grant; Neyns, Bart; Richtig, Erika; Robert, Caroline; Schadendorf, Dirk; Scolyer, Richard; Sondak, Vernon K; Wainstein, Alberto; Weichenthal, Michael; Nuti, Paolo; Melanoma World Society Study Group
    Neoadjuvant or perioperative therapy for melanoma metastasis in clinical practice : An international survey
    In: The Lancet Oncology, Vol. 26, 2025, Nr. 1, pp. 12 – 14
    DOI
  • Kaur, Amanpreet; Webster, Marie R.; Marchbank, Katie; Behera, Reeti; Ndoye, Abibatou; Kugel, Curtis H.; Dang, Vanessa M.; Appleton, Jessica; O’Connell, Michael P.; Cheng, Phil; Valiga, Alexander A.; Morissette, Rachel; McDonnell, Nazli B.; Ferrucci, Luigi; Kossenkov, Andrew V.; Meeth, Katrina; Tang, Hsin-Yao; Yin, Xiangfan; Wood, William H.; Lehrmann, Elin; Becker, Kevin G.; Flaherty, Keith T.; Frederick, Dennie T.; Wargo, Jennifer A.; Cooper, Zachary A.; Tetzlaff, Michael T.; Hudgens, Courtney; Aird, Katherine M.; Zhang, Rugang; Xu, Xiaowei; Liu, Qin; Bartlett, Edmund; Karakousis, Giorgos; Eroglu, Zeynep; Lo, Roger S.; Chan, Matthew; Menzies, Alexander M.; Long, Georgina V.; Johnson, Douglas B.; Sosman, Jeffrey; Schilling, Bastian; Schadendorf, Dirk; Speicher, David W.; Bosenberg, Marcus; Ribas, Antoni; Weeraratna, Ashani T.
    Retraction note: sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance
    In: Nature, Vol. 647, 2025, pp. 544
    DOI (Open Access)
  • Bührer, Emanuel; Kicinski, Michal; Mandala, Mario; Pe, Madeline; Long, Georgina V; Atkinson, Victoria; Blank, Christian U; Haydon, Andrew; Dalle, Stéphane; Khattak, Adnan; Carlino, Matteo S; Meshcheryakov, Andrey; Sandhu, Shahneen; Puig, Susana; Schadendorf, Dirk; Jamal, Rahima; Rutkowski, Piotr; van den Eertwegh, Alfonsus J M; Coens, Corneel; Grebennik, Dmitri; Krepler, Clemens; Robert, Caroline; Eggermont, Alexander M M
    Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054) : Long-term, health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial
    In: The Lancet Oncology, Vol. 25, 2024, Nr. 9, pp. 1202 – 1212
    DOI
  • Gerstung, Moritz; Jolly, Clemency; Leshchiner, Ignaty; Küppers, Ralf; Schadendorf, Dirk
    Author Correction : The evolutionary history of 2,658 cancers
    In: Nature, Vol. 614, 2023, E42
    DOI (Open Access)
  • Weischenfeldt, Joachim; Beroukhim, Rameen; Campbell, Peter J.; Küppers, Ralf; Schadendorf, Dirk
    Author Correction : Patterns of somatic structural variation in human cancer genomes
    In: Nature, Vol. 614, 2023, Nr. 7948, pp. E38
    DOI (Open Access)
  • Calabrese, Claudia; Brazma, Alvis; Brooks, Angela N.; Rätsch, Gunnar; Küppers, Ralf; Schadendorf, Dirk
    Author Correction : Genomic basis for RNA alterations in cancer
    In: Nature, Vol. 614, 2023, Nr. 7948, pp. E37
    DOI (Open Access)
  • Alexandrov, Ludmil B.; Kim, Jaegil; Haradhvala, Nicholas J.; Rozen, Steven G.; Stratton, Michael R.; Küppers, Ralf; Schadendorf, Dirk
    Author Correction: : The repertoire of mutational signatures in human cancer
    In: Nature, Vol. 614, 2023, pp. E41
    DOI (Open Access)
  • Cortés-Ciriano, Isidro; Küppers, Ralf; Schadendorf, Dirk; Park, Peter J.
    Author Correction: Comprehensive analysis of chromothripsis in 2,658 human cancers using whole-genome sequencing
    In: Nature Genetics, Vol. 55, 2023, Nr. 6, 1076
    DOI (Open Access)
  • Akdemir, Kadir C.; Küppers, Ralf; Schadendorf, Dirk; Futreal, P. Andrew
    Author Correction: Disruption of chromatin folding domains by somatic genomic rearrangements in human cancer
    In: Nature Genetics, Vol. 55, 2023, Nr. 6, pp. 1079
    DOI (Open Access)
  • Küppers, Ralf; Schadendorf, Dirk
    Author Correction: Pan-cancer analysis of whole genomes
    In: Nature, Vol. 614, 2023, Nr. 7948, pp. E39
    DOI (Open Access)
  • Zapatka, Marc; Schadendorf, Dirk; Lichter, Peter
    Author Correction: The landscape of viral associations in human cancers
    In: Nature Genetics, Vol. 55, 2023, Nr. 6, pp. 1077
    DOI (Open Access)
  • Cortés-Ciriano, Isidro; Küppers, Ralf; Schadendorf, Dirk; Park, Peter J.
    Comprehensive analysis of chromothripsis in 2,658 human cancers using whole-genome sequencing
    In: Nature Genetics, Vol. 52, 2023, pp. 331 – 341
    DOI (Open Access)
  • Akdemir, Kadir C.; Küppers, Ralf; Schadendorf, Dirk; Futreal, P. Andrew
    Disruption of chromatin folding domains by somatic genomic rearrangements in human cancer
    In: Nature Genetics, Vol. 52, 2023, Nr. 3, pp. 294 – 305
    DOI (Open Access)
  • Gross, Neil D; Miller, David M; Khushalani, Nikhil I; Divi, Vasu; Ruiz, Emily S; Lipson, Evan J; Meier, Friedegund; Su, Yungpo Bernard; Swiecicki, Paul L; Atlas, Jennifer; Geiger, Jessica L; Hauschild, Axel; Choe, Jennifer H; Hughes, Brett G M; Schadendorf, Dirk; Patel, Vishal A; Homsi, Jade; Taube, Janis M; Lim, Annette M; Ferrarotto, Renata; Yoo, Suk-Young; Mathias, Melissa; Han, Hyunsil; Seebach, Frank; Lowy, Israel; Fury, Matthew G; Rischin, Danny
    Neoadjuvant cemiplimab and surgery for stage II–IV cutaneous squamous-cell carcinoma : follow-up and survival outcomes of a single-arm, multicentre, phase 2 study
    In: The Lancet Oncology, Vol. 24, 2023, Nr. 11, pp. 1196 – 1205
    DOI
  • Garbe, Claus; Dummer, Reinhard; Amaral, Teresa; Amaria, Rodabe N.; Ascierto, Paolo A.; Burton, Elizabeth M.; Dreno, Brigitte; Eggermont, Alexander M. M.; Hauschild, Axel; Hoeller, Christoph; Kaufmann, Roland; Lebbe, Celeste; Mandala, Mario; Menzies, Alexander M.; Moreno, David; Michielin, Olivier; Nathan, Paul; Patel, Sapna P.; Robert, Caroline; Schadendorf, Dirk; Lorigan, Paul C.; Scolyer, Richard A.; Tawbi, Hussein A.; van de Wiel, Bart A.; Blank, Christian; Long, Georgina V.
    Neoadjuvant immunotherapy for melanoma is now ready for clinical practice
    In: Nature Medicine, Vol. 29, 2023, Nr. 6, pp. 1310 – 1312
    DOI
  • Illert, A.L.; Stenzinger, A.; Bitzer, M.; Horak, P.; Gaidzik, V.I.; Möller, Y.; Beha, J.; Öner, Ö.; Schmitt, F.; Laßmann, S.; Ossowski, S.; Schaaf, C.P.; Hallek, M.; Brümmendorf, T.H.; Albers, P.; Fehm, T.; Brossart, P.; Glimm, H.; Schadendorf, Dirk; Bleckmann, A.; Brandts, C.H.; Esposito, I.; Mack, E.; Peters, C.; Bokemeyer, C.; Fröhling, S.; Kindler, T.; Algül, H.; Heinemann, V.; Döhner, H.; Bargou, R.; Ellenrieder, V.; Hillemanns, P.; Lordick, F.; Hochhaus, A.; Beckmann, M.W.; Pukrop, T.; Trepel, M.; Sundmacher, L.; Wesselmann, S.; Nettekoven, G.; Kohlhuber, F.; Heinze, O.; Budczies, J.; Werner, M.; Nikolaou, K.; Beer, A.J.; Tabatabai, G.; Weichert, W.; Keilholz, U.; Boerries, M.; Kohlbacher, O.; Duyster, J.; Thimme, R.; Seufferlein, T.; Schirmacher, P.; Malek, N.P.
    The German Network for Personalized Medicine to enhance patient care and translational research
    In: Nature Medicine, Vol. 29, 2023, Nr. 6, pp. 1298 – 1301
    DOI
  • Zapatka, Marc; Küppers, Ralf; Schadendorf, Dirk; Lichter, Peter
    The landscape of viral associations in human cancers
    In: Nature Genetics, 2023, Nr. 52, pp. 320 – 330
    DOI (Open Access)
  • Alexandrov, Ludmil B.; Kim, Jaegil; Haradhvala, Nicholas J.; Rozen, Steven G.; Stratton, Michael R.; Küppers, Ralf; Schadendorf, Dirk
    The repertoire of mutational signatures in human cancer
    In: Nature, Vol. 578, 2023, Nr. 7793, pp. 94 – 101
    DOI (Open Access)
  • Küppers, Ralf; Schadendorf, Dirk; Bristow, Robert G.; Boutros, Paul C.; PCAWG Consortium
    Author Correction : Divergent mutational processes distinguish hypoxic and normoxic tumours
    In: Nature Communications, Vol. 13, 2022, 7569
    DOI (Open Access)
  • Küppers, Ralf; Schadendorf, Dirk; Shuai, Shimin; Stein, Lincoln D.; PCAWG Drivers and Functional Interpretation Working Group; PCAWG Consortium
    Author Correction : Combined burden and functional impact tests for cancer driver discovery using DriverPower
    In: Nature Communications, Vol. 13, 2022, 7571
    DOI (Open Access)
  • Küppers, Ralf; Schadendorf, Dirk; Stein, Lincoln D.; PCAWG Consortium
    Author Correction : A deep learning system accurately classifies primary and metastatic cancers using passenger mutation patterns
    In: Nature Communications, Vol. 13, 2022, 7573
    DOI (Open Access)
  • Küppers, Ralf; Schadendorf, Dirk; Macintyre, Geoff; PCAWG Consortium
    Author Correction : Inferring structural variant cancer cell fraction
    In: Nature Communications, Vol. 13, 2022, 7568
    DOI (Open Access)
  • Küppers, Ralf; Schadendorf, Dirk; Reimand, Jüri; PCAWG Drivers and Functional Interpretation Working Group; PCAWG Consortium
    Author Correction : Integrative pathway enrichment analysis of multivariate omics data
    In: Nature Communications, Vol. 13, 2022, 7570
    DOI (Open Access)
  • Küppers, Ralf; Schadendorf, Dirk; Creighton, Chad J.; PCAWG Consortium
    Author Correction : High-coverage whole-genome analysis of 1220 cancers reveals hundreds of genes deregulated by rearrangement-mediated cis-regulatory alterations
    In: Nature Communications, Vol. 13, 2022, 7572
    DOI (Open Access)
  • Küppers, Ralf; Schadendorf, Dirk; Morris, Quaid D.; PCAWG Consortium
    Author Correction : Reconstructing evolutionary trajectories of mutation signature activities in cancer using TrackSig
    In: Nature Communications, Vol. 13, 2022, 7567
    DOI (Open Access)
  • Küppers, Ralf; Schadendorf, Dirk; Reimand, Jüri; PCAWG Consortium
    Author Correction : Pathway and network analysis of more than 2500 whole cancer genomes
    In: Nature Communications, Vol. 13, 2022, 7566
    DOI (Open Access)
  • Küppers, Ralf; Schadendorf, Dirk; Feuerbach, Lars; PCAWG Consortium
    Author Correction : Genomic footprints of activated telomere maintenance mechanisms in cancer
    In: Nature Communications, Vol. 13, 2022, 7574
    DOI (Open Access)
  • Long, Georgina V; Luke, Jason J; Khattak, Muhammad A; de la Cruz Merino, Luis; Del Vecchio, Michele; Rutkowski, Piotr; Spagnolo, Francesco; Mackiewicz, Jacek; Chiarion-Sileni, Vanna; Kirkwood, John M; Robert, Caroline; Grob, Jean-Jacques; de Galitiis, Federica; Schadendorf, Dirk; Carlino, Matteo S; Mohr, Peter; Dummer, Reinhard; Gershenwald, Jeffrey E; Yoon, Charles H; Wu, Xi Lawrence; Fukunaga-Kalabis, Mizuho; Krepler, Clemens; Eggermont, Alexander M M; Ascierto, Paolo A
    Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716) : distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trial
    In: The Lancet Oncology, Vol. 23, 2022, Nr. 11, pp. 1378 – 1388
    DOI
  • Chauvistré, Heike; Shannan, Batool; Daignault-Mill, Sheena M.; Ju, Robert J.; Picard, Daniel; Egetemaier, Stefanie; Váraljai, Renáta; Gibhardt, Christine S.; Sechi, Antonio; Kaschani, Farnusch; Keminer, Oliver; Stehbens, Samantha J.; Liu, Qin; Yin, Xiangfan; Jeyakumar, Kirujan; Vogel, Felix C. E.; Krepler, Clemens; Rebecca, Vito W.; Kubat, Linda; Lueong, Smiths S.; Forster, Jan; Horn, Susanne; Remke, Marc; Ehrmann, Michael; Paschen, Annette; Becker, Jürgen; Helfrich, Iris; Rauh, Daniel; Kaiser, Markus; Gul, Sheraz; Herlyn, Meenhard; Bogeski, Ivan; Rodríguez-López, José Neptuno; Haass, Nikolas K.; Schadendorf, Dirk; Rösch, Alexander
    Persister state-directed transitioning and vulnerability in melanoma
    32. Deutscher Hautkrebskongress (ADO-Jahrestagung), 14.–17. September 2022, Hannover, Germany,
    In: Nature Communications, Vol. 13, 2022, Nr. 1, pp. 35 – 36
    DOI, Online Full Text (Open Access)
  • Eggermont, Alexander M M; Blank, Christian U; Mandalà, Mario; Long, Georgina V; Atkinson, Victoria G; Dalle, Stéphane; Haydon, Andrew M; Meshcheryakov, Andrey; Khattak, Adnan; Carlino, Matteo S; Sandhu, Shahneen; Larkin, James; Puig, Susana; Ascierto, Paolo A; Rutkowski, Piotr; Schadendorf, Dirk; Koornstra, Rutger; Hernandez-Aya, Leonel; Di Giacomo, Anna Maria; van den Eertwegh, Alfonsus J M; Grob, Jean-Jacques; Gutzmer, Ralf; Jamal, Rahima; Lorigan, Paul C; van Akkooi, Alexander C J; Krepler, Clemens; Ibrahim, Nageatte; Marreaud, Sandrine; Kicinski, Michal; Suciu, Stefan; Robert, Caroline; Menzies, Alex; Lesimple, Thierry; Maio, Michele; Linette, Gerald; Brown, Michael; Hersey, Peter; Svane, Inge Marie; Mortier, Laurent; Schachter, Jacob; Barrow, Catherine; Kudchadkar, Ragini; Song, Xinni; Dutriaux, Caroline; Quaglino, Pietro; Meier, Friedegund; Queirolo, Paola; Stroyakovskiy, Daniil; Bastholt, Lars; Guillot, Bernard; Garbe, Claus; Ortiz Romero, Pablo Luis; Grange, Florent; Mohr, Peter; Algazi, Alain; Bechter, Oliver; Hernberg, Micaela; Arnault, Jean-Philippe; Saiag, Philippe; Loquai, Carmen; Meiss, Frank; Simon, Jan-Christoph; Bar-Sela, Gil; Chiarion Sileni, Vanna; Fitzharris, Bernard; McCrystal, Mike; Parente, Phillip; Baurain, Jean-Francois; Combemale, Patrick; Lebbe, Célèste; Hauschild, Axel; Yamazaki, Naoya; Dummer, Reinhard; Milhem, Mohammed; Dzienis, Marcin; Walker, John; Geoffrois, Lionel; Leccia, Marie-Thérèse; Kretschmer, Lutz; Hendler, Daniel; Lotem, Michal; Mackiewicz, Andrzej; Sekulovic, Lidija; Dunwoodie, Elaine; Hoeller, Christoph; Machet, Laurent; Hassel, Jessica; Hospers, Geke A.P.; Passos, Maria-Jose; Levin, Max; Fehr, Martin; Corrie, Philippa; Waterston, Ashita; Hallmeyer, Sigrun; Schmidt, Henrik; Descamps, Vincent; Lacour, Jean-Philippe; Berking, Carola; Kiecker, Felix; Ferrucci, Pier Francesco; Yokota, Kenji; Aarts, Maureen; Jameson, Michael; Winge-Main, Anna Katharina; Ferreira, Paula; Kim, Kevin; McNeil, Catriona; Hofmann-Wellenhof, Reiner; Kerger, Joseph; Aubin, François; Utikal, Jochen; Ferraresi, Virginia; Inozume, Takashi; Kiyohara, Yoshio; Groenewegen, Gerard; Kapiteijn, Helena; Matkovic, Suzana; Boehncke, Wolf-Henning; Casasola, Richard; Crook, Timothy; Marshall, Ernest; Skytta, Tanja; Avril, Marie-Francoise; Jouary, Thomas; Hein, Rüdiger; Terheyden, Patrick; Aoi, Jun; Takenouchi, Tatsuya; Straume, Oddbjorn; Martins, César; Mukhametshina, Guzel; Nathan, Paul
    Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054) : distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial
    In: The Lancet Oncology, Vol. 22, 2021, Nr. 5, pp. 643 – 654
    DOI
  • Bottomley, Andrew; Coens, Corneel; Mierzynska, Justyna; Blank, Christian U; Mandalà, Mario; Long, Georgina V; Atkinson, Victoria G; Dalle, Stéphane; Haydon, Andrew M; Meshcheryakov, Andrey; Khattak, Adnan; Carlino, Matteo S; Sandhu, Shahneen; Puig, Susana; Ascierto, Paolo A; Larkin, James; Lorigan, Paul C; Rutkowski, Piotr; Schadendorf, Dirk; Koornstra, Rutger; Hernandez-Aya, Leonel; Di Giacomo, Anna Maria; van den Eertwegh, Alfonsus J M; Grob, Jean-Jacques; Gutzmer, Ralf; Jamal, Rahima; van Akkooi, Alexander C J; Krepler, Clemens; Ibrahim, Nageatte; Marreaud, Sandrine; Kicinski, Michal; Suciu, Stefan; Robert, Caroline; Eggermont, Alexander M M; Lesimple, Thierry; Maio, Michele; Linette, Gerald; Mortier, Laurent; Svane, Inge Marie; Schachter, Jacob; Brown, Michael; Hersey, Peter; Barrow, Catherine; Kudchadkar, Ragini; Dutriaux, Caroline; Song, Xinni; Quaglino, Pietro; Queirolo, Paola; Meier, Friedegund; Stroyakovskiy, Daniil; Guillot, Bernard; Romero, Pablo Luis Ortiz; Bastholt, Lars; Garbe, Claus; Grange, Florent; Mohr, Peter; Algazi, Alain; Bechter, Oliver; Hernberg, Micaela; Loquai, Carmen; Meiss, Frank; Chiarion Sileni, Vanna; Bar-Sela, Gil; Fitzharris, Bernard; Saiag, Philippe; Arnault, Jean-Philippe; Simon, Jan-Christoph; Stephens, Rosalie; Baurain, Jean-Francois; Lebbe, Célèste; Combemale, Patrick; Dummer, Reinhard; Hauschild, Axel; Parente, Phillip; Yamazaki, Naoya; Milhem, Mohammed; Leccia, Marie-Thérèse; Geoffrois, Lionel; Kretschmer, Lutz; Dunwoodie, Elaine; Walker, John; Lotem, Michal; Hendler, Daniel; Mackiewicz, Andrzej; Sekulovic, Lidija; Dzienis, Marcin; Hospers, Geke A.P.; Siano, Marco; Hassel, Jessica; Corrie, Philippa; Passos, Maria-Jose; Levin, Max; Hoeller, Christoph; Machet, Laurent; Hallmeyer, Sigrun; Waterston, Ashita; Descamps, Vincent; Kiecker, Felix; Aarts, Maureen; Schmidt, Henrik; Raimundo, Ana; Nyakas, Marta; Lacour, Jean-Philippe; Berking, Carola; Ferrucci, Pier Francesco; Jameson, Michael; Kim, Kevin; Yokota, Kenji; Kerger, Joseph; Aubin, François; Groenewegen, Gerard; Kapiteijn, Helena; Boehncke, Wolf-Henning; Utikal, Jochen; Casasola, Richard; Marshall, Ernest; Ferraresi, Virginia; Richtig, Erika; Matkovic, Suzana; Inozume, Takashi; Crook, Timothy; McNeil, Catriona; Kiyohara, Yoshio; Avril, Marie-Francoise; Hein, Rüdiger; Terheyden, Patrick; Nathan, Paul; Aoi, Jun; Skytta, Tanja; Jouary, Thomas; Takenouchi, Tatsuya; Straume, Oddbjorn; Martins, César; Mukhametshina, Guzel
    Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054) : health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial
    In: The Lancet Oncology, Vol. 22, 2021, Nr. 5, pp. 655 – 664
    DOI, Online Full Text (Open Access)
  • Syeda, Mahrukh M.; Wiggins, Jennifer M.; Corless, Broderick C; Long, Georgina V.; Flaherty, Keith T.; Schadendorf, Dirk; Nathan, Paul D.; Robert, Caroline; Ribas, Antoni; Davies, Michael A.; Grob, Jean Jacques; Gasal, Eduard; Squires, Matthew; Marker, Mahtab; Garrett, James; Brase, Jan C.; Polsky, David
    Circulating tumour DNA in patients with advanced melanoma treated with dabrafenib or dabrafenib plus trametinib : A clinical validation study
    In: The Lancet Oncology, Vol. 22, 2021, Nr. 3, pp. 370 – 380
    DOI, Online Full Text (Open Access)
  • Le Rhun, E.; Guckenberger, M.; Smits, M.; Dummer, R.; Bachelot, T.; Sahm, F.; Galldiks, N.; de Azambuja, E.; Berghoff, A.S.; Metellus, P.; Peters, S.; Hong, Y.-K.; Winkler, F.; Schadendorf, Dirk; van den Bent, M.; Seoane, J.; Stahel, R.; Minniti, G.; Wesseling, P.; Weller, M.; Preusser, M.
    EANO–ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumours
    In: Annals of Oncology, Vol. 32, 2021, Nr. 11, pp. 1332 – 1347
    DOI (Open Access)
  • Frangieh, Chris J.; Melms, Johannes C.; Thakore, Pratiksha I.; Geiger-Schuller, Kathryn R.; Ho, Patricia; Luoma, Adrienne M.; Cleary, Brian; Jerby-Arnon, Livnat; Malu, Shruti; Cuoco, Michael S.; Zhao, Maryann; Ager, Casey R.; Rogava, Meri; Hovey, Lila; Rotem, Asaf; Bernatchez, Chantale; Wucherpfennig, Kai W.; Johnson, Bruce E.; Rozenblatt-Rosen, Orit; Schadendorf, Dirk; Regev, Aviv; Izar, Benjamin
    Multimodal pooled Perturb-CITE-seq screens in patient models define mechanisms of cancer immune evasion
    In: Nature Genetics, Vol. 53, 2021, Nr. 3, pp. 332 – 341
    DOI (Open Access)
  • Küppers, Ralf; Schadendorf, Dirk; Stein, Lincoln D.; PCAWG Consortium
    A deep learning system accurately classifies primary and metastatic cancers using passenger mutation patterns
    In: Nature Communications, Vol. 11, 2020, 728
    DOI (Open Access)
  • Dummer, Reinhard; Brase, Jan C.; Garrett, James; Campbell, Catarina D.; Gasal, Eduard; Squires, Matthew; Gusenleitner, Daniel; Santinami, Mario; Atkinson, Victoria; Mandalà, Mario; Chiarion-Sileni, Vanna; Flaherty, Keith; Larkin, James; Robert, Caroline; Kefford, Richard; Kirkwood, John M.; Hauschild, Axel; Schadendorf, Dirk; Long, Georgina V.
    Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV⁶⁰⁰-mutant, stage III melanoma (COMBI-AD) : Exploratory biomarker analyses from a randomised, phase 3 trial
    In: The Lancet Oncology, Vol. 21, 2020, Nr. 3, pp. 358 – 372
    DOI, Online Full Text (Open Access)
  • Eggermont, Alexander M. M.; Kicinski, Michal; Blank, Christian U.; Mandala, Mario; Long, Georgina V.; Atkinson, Victoria; Dalle, Stéphane; Haydon, Andrew; Khattak, Adnan; Carlino, Matteo S.; Sandhu, Shahneen; Larkin, James; Puig, Susana; Ascierto, Paolo A.; Rutkowski, Piotr; Schadendorf, Dirk; Koornstra, Rutger; Hernandez-Aya, Leonel; Di Giacomo, Anna Maria; Van Den Eertwegh, Alfonsus J. M.; Grob, Jean-Jacques; Gutzmer, Ralf; Jamal, Rahima; Lorigan, Paul C.; Krepler, Clemens; Ibrahim, Nageatte; Marreaud, Sandrine; Van Akkooi, Alexander; Robert, Caroline; Suciu, Stefan
    Association between Immune-Related Adverse Events and Recurrence-Free Survival among Patients with Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo : A Secondary Analysis of a Randomized Clinical Trial
    In: JAMA Oncology, Vol. 6, 2020, Nr. 4, pp. 519 – 527
    DOI (Open Access)
  • Puzanov, Igor; Ribas, Antoni; Robert, Caroline; Schachter, Jacob; Nyakas, Marta; Daud, Adil; Arance, Ana; Carlino, Matteo S.; O'Day, Steven J.; Long, Georgina V.; Margolin, Kim A.; Dummer, Reinhard; Schadendorf, Dirk; Lutzky, Jose; Ascierto, Paolo A.; Tarhini, Ahmad; Lin, Jianxin; Mogg, Robin; Homet Moreno, Blanca; Ibrahim, Nageatte; Hamid, Omid
    Association of BRAF V600E/K Mutation Status and Prior BRAF/MEK Inhibition with Pembrolizumab Outcomes in Advanced Melanoma : Pooled Analysis of 3 Clinical Trials
    In: JAMA Oncology, Vol. 6, 2020, Nr. 8, pp. 1256 – 1264
    DOI
  • Liu, David; Schilling, Bastian; Liu, Derek; Sucker, Antje; Livingstone, Elisabeth; Jerby-Arnon, Livnat; Zimmer, Lisa; Gutzmer, Ralf; Satzger, Imke; Loquai, Carmen; Grabbe, Stephan; Vokes, Natalie; Margolis, Claire A.; Conway, Jake; He, Meng Xiao; Elmarakeby, Haitham; Dietlein, Felix; Miao, Diana; Tracy, Adam; Gogas, Helen; Goldinger, Simone M.; Utikal, Jochen; Blank, Christian U.; Rauschenberg, Ricarda; von Bubnoff, Dagmar; Krackhardt, Angela; Weide, Benjamin; Haferkamp, Sebastian; Kiecker, Felix; Izar, Ben; Garraway, Levi; Regev, Aviv; Flaherty, Keith; Paschen, Annette; Van Allen, Eliezer M.; Schadendorf, Dirk
    Author Correction: Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma
    In: Nature Medicine, Vol. 26, 2020, Nr. 7, pp. 1147
    DOI (Open Access)
  • Küppers, Ralf; Schadendorf, Dirk
    Author Correction: Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples
    In: Nature Communications, Vol. 11, 2020, Nr. 1, pp. 6232
    DOI (Open Access)
  • Cabrita, Rita; Lauss, Martin; Sanna, Adriana; Donia, Marco; Skaarup Larsen, Mathilde; Mitra, Shamik; Johansson, Iva; Phung, Bengt; Harbst, Katja; Vallon-Christersson, Johan; van Schoiack, Alison; Lövgren, Kristina; Warren, Sarah; Jirström, Karin; Olsson, Håkan; Pietras, Kristian; Ingvar, Christian; Isaksson, Karolin; Schadendorf, Dirk; Schmidt, Henrik; Bastholt, Lars; Carneiro, Ana; Wargo, Jennifer A.; Svane, Inge Marie; Jönsson, Göran
    Author Correction: Tertiary lymphoid structures improve immunotherapy and survival in melanoma
    In: Nature, Vol. 580, 2020, Nr. 7801, pp. E1
    DOI (Open Access)
  • Brenner, Ellen; Schörg, Barbara F.; Ahmetlić, Fatima; Wieder, Thomas; Hilke, Franz Joachim; Simon, Nadine; Schroeder, Christopher; Demidov, German; Riedel, Tanja; Fehrenbacher, Birgit; Schaller, Martin; Forschner, Andrea; Eigentler, Thomas; Niessner, Heike; Sinnberg, Tobias; Böhm, Katharina S.; Hömberg, Nadine; Braumüller, Heidi; Dauch, Daniel; Zwirner, Stefan; Zender, Lars; Sonanini, Dominik; Geishauser, Albert; Bauer, Jürgen; Eichner, Martin; Jarick, Katja J.; Beilhack, Andreas; Biskup, Saskia; Döcker, Dennis; Schadendorf, Dirk; Quintanilla-Martinez, Leticia; Pichler, Bernd J.; Kneilling, Manfred; Mocikat, Ralph; Röcken, Martin
    Cancer immune control needs senescence induction by interferon-dependent cell cycle regulator pathways in tumours
    In: Nature Communications, Vol. 11, 2020, Nr. 1, pp. 1335
    DOI (Open Access)
  • Migden, Michael R.; Khushalani, Nikhil I.; Chang, Anne Lynn S.; Lewis, Karl D.; Schmults, Chrysalyne D.; Hernandez-Aya, Leonel; Meier, Friedegund; Schadendorf, Dirk; Guminski, Alexander; Hauschild, Axel; Wong, Deborah J.; Daniels, Gregory A.; Berking, Carola; Jankovic, Vladimir; Stankevich, Elizabeth; Booth, Jocelyn; Li, Siyu; Weinreich, David M.; Yancopoulos, George D.; Lowy, Israel; Fury, Matthew G.; Rischin, Danny
    Cemiplimab in locally advanced cutaneous squamous cell carcinoma : results from an open-label, phase 2, single-arm trial
    In: The Lancet Oncology, Vol. 21, 2020, Nr. 2, pp. 294 – 305
    DOI, Online Full Text (Open Access)
  • Dummer, Reinhard; Lebbé, Celeste; Atkinson, Victoria; Mandalà, Mario; Nathan, Paul D.; Arance, Ana; Richtig, Erika; Yamazaki, Naoya; Robert, Caroline; Schadendorf, Dirk; Tawbi, Hussein A.; Ascierto, Paolo A.; Ribas, Antoni; Flaherty, Keith T.; Pakhle, Neha; Campbell, Catarina D.; Gusenleitner, Daniel; Masood, Aisha; Brase, Jan C.; Gasal, Eduard; Long, Georgina V.
    Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma : safety run-in and biomarker cohorts of COMBI-i
    In: Nature Medicine, Vol. 26, 2020, Nr. 10, pp. 1557 – 1563
    DOI
  • Küppers, Ralf; Schadendorf, Dirk; Shuai, Shimin; Stein, Lincoln D.
    Combined burden and functional impact tests for cancer driver discovery using DriverPower
    In: Nature Communications, Vol. 11, 2020, 734
    DOI (Open Access)
  • Küppers, Ralf; Schadendorf, Dirk; Bristow, Robert G.; Boutros, Paul C.; PCAWG Consortium
    Divergent mutational processes distinguish hypoxic and normoxic tumours
    In: Nature Communications, Vol. 11, 2020, 737
    DOI (Open Access)
  • Ugurel, Selma; Schadendorf, Dirk; Horny, K.; Sucker, Antje; Schramm, Sabine; Utikal, Jochen; Pföhler, Claudia; Herbst, Rudolf A.; Schilling, B.; Blank, Christian U.; Becker, Jürgen; Paschen, Annette; Zimmer, Lisa; Livingstone, Elisabeth; Horn, Peter; Rebmann, Vera
    Elevated baseline serum PD-1 or PD-L1 predicts poor outcome of PD-1 inhibition therapy in metastatic melanoma
    In: Annals of Oncology, Vol. 31, 2020, Nr. 1, pp. 144 – 152
    DOI (Open Access)
  • Landi, Maria Teresa; Bishop, D. Timothy; MacGregor, Stuart; Machiela, Mitchell J.; Stratigos, Alexander J.; Ghiorzo, Paola; Brossard, Myriam; Calista, Donato; Choi, Jiyeon; Fargnoli, Maria Concetta; Zhang, Tongwu; Rodolfo, Monica; Trower, Adam J.; Menin, Chiara; Martinez, Jacobo; Hadjisavvas, Andreas; Song, Lei; Stefanaki, Irene; Scolyer, Richard; Yang, Rose; Goldstein, Alisa M.; Potrony, Miriam; Kypreou, Katerina P.; Pastorino, Lorenza; Queirolo, Paola; Pellegrini, Cristina; Cattaneo, Laura; Zawistowski, Matthew; Gimenez-Xavier, Pol; Rodriguez, Arantxa; Elefanti, Lisa; Manoukian, Siranoush; Rivoltini, Licia; Smith, Blair H.; Loizidou, Maria A.; Del Regno, Laura; Massi, Daniela; Mandala, Mario; Khosrotehrani, Kiarash; Akslen, Lars A.; Amos, Christopher I.; Andresen, Per A.; Avril, Marie-Françoise; Azizi, Esther; Soyer, H. Peter; Bataille, Veronique; Dalmasso, Bruna; Bowdler, Lisa M.; Burdon, Kathryn P.; Chen, Wei V.; Codd, Veryan; Craig, Jamie E.; Dębniak, Tadeusz; Falchi, Mario; Fang, Shenying; Friedman, Eitan; Simi, Sarah; Galan, Pilar; Garcia-Casado, Zaida; Gillanders, Elizabeth M.; Gordon, Scott; Green, Adele; Gruis, Nelleke A.; Hansson, Johan; Harland, Mark; Harris, Jessica; Helsing, Per; Henders, Anjali; Hočevar, Marko; Höiom, Veronica; Hunter, David; Ingvar, Christian; Kumar, Rajiv; Lang, Julie; Lathrop, G. Mark; Lee, Jeffrey E.; Li, Xin; Lubiński, Jan; Mackie, Rona M.; Malt, Maryrose; Malvehy, Josep; McAloney, Kerrie; Mohamdi, Hamida; Molven, Anders; Moses, Eric K.; Neale, Rachel E.; Novaković, Srdjan; Nyholt, Dale R.; Olsson, Håkan; Orr, Nicholas; Fritsche, Lars G.; Puig-Butille, Joan Anton; Qureshi, Abrar A.; Radford-Smith, Graham L.; Randerson-Moor, Juliette; Requena, Celia; Rowe, Casey; Samani, Nilesh J.; Sanna, Marianna; Schadendorf, Dirk; Schulze, Hans-Joachim; Simms, Lisa A.; Smithers, Mark; Song, Fengju; Swerdlow, Anthony J.; van der Stoep, Nienke; Kukutsch, Nicole A.; Visconti, Alessia; Wallace, Leanne; Ward, Sarah V.; Wheeler, Lawrie; Sturm, Richard A.; Hutchinson, Amy; Jones, Kristine; Malasky, Michael; Vogt, Aurelie; Zhou, Weiyin; Pooley, Karen A.; Elder, David E.; Han, Jiali; Hicks, Belynda; Hayward, Nicholas K.; Kanetsky, Peter A.; Brummett, Chad; Montgomery, Grant W.; Olsen, Catherine M.; Hayward, Caroline; Dunning, Alison M.; Martin, Nicholas G.; Evangelou, Evangelos; Mann, Graham J.; Long, Georgina; Pharoah, Paul D. P.; Easton, Douglas F.; Barrett, Jennifer H.; Cust, Anne E.; Abecasis, Goncalo; Duffy, David L.; Whiteman, David C.; Gogas, Helen; De Nicolo, Arcangela; Tucker, Margaret A.; Newton-Bishop, Julia A.; Peris, Ketty; Chanock, Stephen J.; Demenais, Florence; Brown, Kevin M.; Puig, Susana; Nagore, Eduardo; Shi, Jianxin; Iles, Mark M.; Law, Matthew H.
    Genome-wide association meta-analyses combining multiple risk phenotypes provide insights into the genetic architecture of cutaneous melanoma susceptibility
    In: Nature Genetics, Vol. 52, 2020, Nr. 5, pp. 494 – 504
    DOI, Online Full Text (Open Access)
  • Küppers, Ralf; Schadendorf, Dirk; Feuerbach, Lars; PCAWG Consortium
    Genomic footprints of activated telomere maintenance mechanisms in cancer
    In: Nature Communications, Vol. 11, 2020, 733
    DOI (Open Access)
  • Küppers, Ralf; Schadendorf, Dirk; Creighton, Chad J.; PCAWG Consortium
    High-coverage whole-genome analysis of 1220 cancers reveals hundreds of genes deregulated by rearrangement-mediated cis-regulatory alterations
    In: Nature Communications, Vol. 11, 2020, 736
    DOI (Open Access)
  • Küppers, Ralf; Schadendorf, Dirk; Cmero, Marek; Macintyre, Geoff; PCAWG Consortium
    Inferring structural variant cancer cell fraction
    In: Nature Communications, Vol. 11, 2020, 730
    DOI (Open Access)
  • Conway, Jake R.; Dietlein, Felix; Taylor-Weiner, Amaro; AlDubayan, Saud; Vokes, Natalie; Keenan, Tanya; Reardon, Brendan; He, Meng Xiao; Margolis, Claire A.; Weirather, Jason L.; Haq, Rizwan; Schilling, Bastian; Stephen Hodi, F.; Schadendorf, Dirk; Liu, David; Van Allen, Eliezer M.
    Integrated molecular drivers coordinate biological and clinical states in melanoma
    In: Nature Genetics, Vol. 52, 2020, Nr. 12, pp. 1373 – 1383
    DOI, Online Full Text (Open Access)
  • Küppers, Ralf; Schadendorf, Dirk; Reimand, Jüri; PCAWG Drivers and Functional Interpretation Working Group; PCAWG Consortium
    Integrative pathway enrichment analysis of multivariate omics data
    In: Nature Communications, Vol. 11, 2020, 735
    DOI (Open Access)
  • Tasdogan, Alpaslan; Faubert, Brandon; Ramesh, Vijayashree; Ubellacker, Jessalyn M.; Shen, Bo; Solmonson, Ashley; Murphy, Malea M.; Gu, Zhimin; Gu, Wen; Martin, Misty; Kasitinon, Stacy Y.; Vandergriff, Travis; Mathews, Thomas P.; Zhao, Zhiyu; Schadendorf, Dirk; DeBerardinis, Ralph J.; Morrison, Sean J.
    Metabolic heterogeneity confers differences in melanoma metastatic potential
    In: Nature, Vol. 577, 2020, Nr. 7788, pp. 115 – 120
    DOI, Online Full Text (Open Access)
  • Küppers, Ralf; Schadendorf, Dirk; ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium; et al.
    Pan-cancer analysis of whole genomes
    In: Nature, Vol. 578, 2020, Nr. 7793, pp. 82 – 93
    DOI (Open Access)
  • Küppers, Ralf; Schadendorf, Dirk
    Pathway and network analysis of more than 2500 whole cancer genomes
    In: Nature Communications, Vol. 11, 2020, 729
    DOI (Open Access)
  • Ascierto, P.A.; Lewis, K.D.; Di Giacomo, A.M.; Demidov, L.; Mandalà, M.; Bondarenko, I.; Herbert, C.; Mackiewicz, A.; Rutkowski, P.; Guminski, A.; Simmons, B.; Ye, C.; Hooper, G.; Wongchenko, M.J.; Goodman, G.R.; Yan, Y.; Schadendorf, Dirk
    Prognostic impact of baseline tumour immune infiltrate on disease-free survival in patients with completely resected, BRAFv⁶⁰⁰ mutation–positive melanoma receiving adjuvant vemurafenib
    In: Annals of Oncology, Vol. 31, 2020, Nr. 1, pp. 153 – 159
    DOI (Open Access)
  • Dummer, Reinhard; Ascierto, Paolo A.; Nathan, Paul; Robert, Caroline; Schadendorf, Dirk
    Rationale for Immune Checkpoint Inhibitors plus Targeted Therapy in Metastatic Melanoma : A Review
    In: JAMA Oncology, Vol. 6, 2020, Nr. 12, pp. 1957 – 1966
    DOI
  • Küppers, Ralf; Schadendorf, Dirk; Morris, Quaid D.; PCAWG Consortium
    Reconstructing evolutionary trajectories of mutation signature activities in cancer using TrackSig
    In: Nature Communications, Vol. 11, 2020, 731
    DOI (Open Access)
  • Küppers, Ralf; Schadendorf, Dirk
    Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples
    In: Nature Communications, Vol. 11, 2020, Nr. 1, pp. 4748
    DOI (Open Access)
  • Küppers, Ralf; Schadendorf, Dirk; PCAWG Tumour Subtypes and Clinical Translation; PCAWG Consortium
    Sex differences in oncogenic mutational processes
    In: Nature Communications, Vol. 11, 2020, Nr. 1, pp. 4330
    DOI (Open Access)
  • Cabrita, Rita; Lauss, Martin; Sanna, Adriana; Donia, Marco; Larsen, Mathilde; Schadendorf, Dirk
    Tertiary lymphoid structures improve immunotherapy and survival in melanoma
    In: Nature, Vol. 577, 2020, Nr. 7791, pp. 561 – 565
    DOI
  • Liu, David; Schilling, Bastian; Liu, Derek; Sucker, Antje; Livingstone, Elisabeth; Jerby-Amon, Livnat; Zimmer, Lisa; Gutzmer, Ralf; Satzger, Imke; Loquai, Carmen; Grabbe, Stephan; Vokes, Natalie; Margolis, Claire A.; Conway, Jake; He, Meng Xiao; Elmarakeby, Haitham; Dietlein, Felix; Miao, Diana; Tracy, Adam; Gogas, Helen; Goldinger, Simone M.; Utikal, Jochen; Blank, Christian U.; Rauschenberg, Ricarda; Bubnoff, Dagmar von; Krackhardt, Angela; Weide, Benjamin; Haferkamp, Sebastian; Kiecker, Felix; Izar, Ben; Garraway, Levi; Regev, Aviv; Flaherty, Keith; Paschen, Annette; Allen, Eliezer M. van; Schadendorf, Dirk
    Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma
    In: Nature Medicine, Vol. 25, 2019, Nr. 12, pp. 1916 – 1927
    DOI (Open Access)
  • Urbonas, Vincas; Schadendorf, Dirk; Zimmer, Lisa; Danson, Sarah J.; Marshall, Ernest; Corrie, Pippa G.; Wheater, Matthew J.; Plummer, E.; Mauch, Cornelia; Scudder, Claire; Goff, Matthew; Love, Sharon B.; Mohammed, S.B.; Middleton, Mark R.
    Paclitaxel with or without trametinib or pazopanib in advanced wild-type BRAF melanoma (PACMEL) : a multicentre, open-label, randomised, controlled phase II trial
    In: Annals of Oncology, Vol. 30, 2019, Nr. 2, pp. 317 – 324
    DOI (Open Access)
  • Schadendorf, Dirk; Hauschild, Axel; Santinami, Mario; Atkinson, Victoria; Mandalà, Mario; Chiarion-Sileni, Vanna; Larkin, James; Nyakas, Marta; Dutriaux, Caroline; Haydon, Andrew; Robert, Caroline; Mortier, Laurent; Lesimple, Thierry; Plummer, Ruth; Schachter, Jacob; Dasgupta, Kohinoor; Manson, Stephanie; Koruth, Roy; Mookerjee, Bijoyesh; Kefford, Richard; Dummer, Reinhard; Kirkwood, John M.; Long, Georgina V.
    Patient-reported outcomes in patients with resected, high-risk melanoma with BRAFV600E or BRAFV600K mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD) : a randomised, placebo-controlled, phase 3 trial
    In: The Lancet Oncology, Vol. 20, 2019, Nr. 5, pp. 701 – 710
    DOI
  • Schadendorf, Dirk; Melanoma GWAS Consortium
    Publisher Correction : Novel pleiotropic risk loci for melanoma and nevus density implicate multiple biological pathways
    In: Nature Communications, Vol. 10, 2019, Nr. 1, pp. 299
    DOI (Open Access)
  • Duffy, David L.; Zhu, Gu; Li, Xin; Sanna, Marianna; Jacobs, Leonie C.; Evans, David M.; Yazar, Seyhan; Beesley, Jonathan; Lawrence, Matthew H.; Kraft, Peter; Visconti, Alessia; Taylor, John C.; Lui, Fan; Wright, Margaret J.; Henders, Anjali K.; Bowdler, Lisa; Glass, Dan; Ikram, Arfan M.; Uitterlinden, André G.; Madden, Pamela A.; Heath, Andrew C.; Nelson, Elliot C.; Green, Adele C.; Chanock, Stephen; Barrett, Jennifer H.; Brown, Matthew A.; Hayward, Nicholas K.; MacGregor, Stuart; Sturm, Richard A.; Hewitt, Alex W.; Leenhardt, Jeffrey E.; Brossard, Myriam; Moses, Eric K.; Song, Fengju; Kumar, Rajiv; Easton, Douglas F.; Pharoah, Paul D. P.; Swerdlow, Anthony J.; Kypreou, Katerina P.; Harland, Mark; Randerson-Moor, Juliette; Akslen, Lars A.; Andresen, Per A.; Avril, Marie-Françoise; Azizi, Esther; Scarrà, Giovanna Bianchi; Brown, Kevin M.; Dębniak, Tadeusz; Elder, David E.; Fang, Shenying; Friedman, Eitan; Galan, Pilar; Ghiorzo, Paola; Gillanders, Elizabeth M.; Goldstein, Alisa M.; Gruis, Nelleke A.; Hansson, Johan; Helsing, Per; Hočevar, Marko; Höiom, Veronica; Ingvar, Christian; Kanetsky, Peter A.; Chen, Wei V.; Landi, Maria Teresa; Lang, Julie; Lathrop, G. Mark; Lubiński, Jan; Mackie, Rona M.; Mann, Graham J.; Molven, Anders; Novaković, Srdjan; Olsson, Håkan; Puig, Susana; Puig-Butille, Joan Anton; Radford-Smith, Graham L.; van Doorn, Remco; Whiteman, David C.; Craig, Jamie E.; Schadendorf, Dirk; Simms, Lisa A.; Burdon, Kathryn P.; Nyholt, Dale R.; Pooley, Karen A.; Orr, Nicholas; Stratigos, Alexander J.; Cust, Anne E.; Ward, Sarah V.; Schulze, Hans-Joachim; Dunning, Alison M.; Demenais, Florence; Amos, Christopher I.; Kayser, Manfred; Hunter, David J.; Newton Bishop, Julia A.; Spector, Timothy D.; Montgomery, Grant W.; Mackey, David A.; Smith, George Davey; Nijsten, Tamar E.; Bishop, D. Timothy; Bataille, Veronique; Falchi, Mario; Han, Jiali; Martin, Nicholas G.
    Publisher Correction: Novel pleiotropic risk loci for melanoma and nevus density implicate multiple biological pathways
    In: Nature Communications, Vol. 10, 2019, Nr. 1, pp. 299
    DOI (Open Access)
  • Ascierto, Paolo A.; Long, Georgina V.; Robert, Caroline; Brady, Benjamin; Dutriaux, Caroline; Di Giacomo, Anna Maria; Mortier, Laurent; Hassel, Jessica C.; Rutkowski, Piotr; McNeil, Catriona; Kalinka-Warzocha, Ewa; Savage, Kerry J.; Hernberg, Micaela M.; Lebbé, Celeste; Charles, Julie; Mihalcioiu, Catalin; Chiarion-Sileni, Vanna; Mauch, Cornelia; Cognetti, Francesco; Ny, Lars; Arance, Ana; Svane, Inge Marie; Schadendorf, Dirk; Gogas, Helen; Saci, Abdel; Jiang, Joel; Rizzo, Jasmine; Atkinson, Victoria
    Survival Outcomes in Patients with Previously Untreated BRAF Wild-Type Advanced Melanoma Treated with Nivolumab Therapy : Three-Year Follow-up of a Randomized Phase 3 Trial
    In: JAMA Oncology, Vol. 5, 2019, Nr. 2, pp. 187 – 194
    DOI
  • Schadendorf, Dirk; Livingstone, Elisabeth; Zimmer, Lisa
    Treatment in metastatic melanoma : Time to re-think
    In: Annals of Oncology, Vol. 30, 2019, Nr. 4, pp. 501 – 503
    DOI (Open Access)
  • Jerby-Arnon, Livnat; Shah, Parin; Cuoco, Michael S.; Rodman, Christopher; Su, Mei-Ju; Melms, Johannes C.; Leeson, Rachel; Kanodia, Abhay; Mei, Shaolin; Lin, Jia-Ren; Wang, Shu; Rabasha, Bokang; Liu, David; Zhang, Gao; Margolais, Claire; Ashenberg, Orr; Ott, Patrick A.; Buchbinder, Elizabeth I.; Haq, Rizwan; Hodi, F. Stephen; Boland, Genevieve M.; Sullivan, Ryan J.; Frederick, Dennie T.; Miao, Benchun; Moll, Tabea; Flaherty, Keith T.; Herlyn, Meenhard; Jenkins, Russell W.; Thummalapalli, Rohit; Kowalczyk, Monika S.; Cañadas, Israel; Schilling, Bastian; Cartwright, Adam N.R.; Luoma, Adrienne M.; Malu, Shruti; Hwu, Patrick; Bernatchez, Chantale; Forget, Marie-Andrée; Barbie, David A.; Shalek, Alex K.; Tirosh, Itay; Sorger, Peter K.; Wucherpfennig, Kai; Van Allen, Eliezer M.; Schadendorf, Dirk; Johnson, Bruce E.; Rotem, Asaf; Rozenblatt-Rosen, Orit; Garraway, Levi A.; Yoon, Charles H.; Izar, Benjamin; Regev, Aviv
    A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade
    In: Cell, Vol. 175, 2018, Nr. 4, pp. 984 – 997.e24
    DOI (Open Access)
  • Grob, Jean Jacques; Garbe, Claus; Ascierto, Paolo; Larkin, James; Dummer, Reinhard; Schadendorf, Dirk
    Adjuvant melanoma therapy with new drugs : Should physicians continue to focus on metastatic disease or use it earlier in primary melanoma?
    In: The Lancet Oncology, Vol. 19, 2018, Nr. 12, pp. e720 – e725
    DOI
  • Maio, Michele; Lewis, Karl; Demidov, Lev; Mandalà, Mario; Bondarenko, Igor; Ascierto, Paolo A; Herbert, Christopher; Mackiewicz, Andrzej; Rutkowski, Piotr; Guminski, Alexander; Goodman, Grant R; Simmons, Brian; Ye, Chenglin; Yan, Yibing; Schadendorf, Dirk; BRIM8 Investigators
    Adjuvant vemurafenib in resected, BRAF mutation-positive melanoma (BRIM8) : a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial
    In: The Lancet Oncology, Vol. 19, 2018, Nr. 4, pp. 510 – 520
    DOI
  • Atkinson, Victoria G.; Hauschild, Axel; Santinami, Mario; Mandala, Mario; Chiarion Sileni, Vanna; Larkin, James M. G.; Nyakas, Marta S.; Dutriaux, Caroline; Haydon, Andrew M. M.; Mortier, Laurent; Robert, Caroline; Schachter, Jacob M.; Schadendorf, Dirk; Feng, X.; Jong, Egbert de; Mookerjee, Bijoyesh P.; Kefford, Rick F.; Dummer, Reinhard G.; Kirkwood, John M.; Long, Georgina V.
    Adverse events (AEs) over time in patients (pts) treated with adjuvant dabrafenib plus trametinib (D + T) or placebo (Pbo) in the COMBI-AD trial
    In: Annals of Oncology, Vol. 29, 2018, Nr. Suppl. 8, pp. viii446
    DOI (Open Access)
  • McQuade, Jennifer L; Daniel, Carrie R; Hess, Kenneth R; Mak, Carmen; Wang, Daniel Y; Rai, Rajat R; Park, John J; Haydu, Lauren E; Spencer, Christine; Wongchenko, Matthew; Lane, Stephen; Lee, Dung-Yang; Kaper, Mathilde; McKean, Meredith; Beckermann, Kathryn E; Rubinstein, Samuel M; Rooney, Isabelle; Musib, Luna; Budha, Nageshwar; Hsu, Jessie; Nowicki, Theodore S; Avila, Alexandre; Haas, Tomas; Puligandla, Maneka; Lee, Sandra; Fang, Shenying; Wargo, Jennifer A; Gershenwald, Jeffrey E; Lee, Jeffrey E; Hwu, Patrick; Chapman, Paul B; Sosman, Jeffrey A; Schadendorf, Dirk; Grob, Jean-Jacques; Flaherty, Keith T; Walker, Dana; Yan, Yibing; McKenna, Edward; Legos, Jeffrey J; Carlino, Matteo S; Ribas, Antoni; Kirkwood, John M; Long, Georgina V; Johnson, Douglas B; Menzies, Alexander M; Davies, Michael A
    Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy : a retrospective, multicohort analysis
    In: The Lancet Oncology, Vol. 19, 2018, Nr. 3, pp. 310 – 322
    DOI, Online Full Text (Open Access)
  • Shukla, Sachet A.; Bachireddy, Pavan; Schilling, Bastian; Galonska, Christina; Zhan, Qian; Bango, Clyde; Langer, Rupert; Lee, Patrick C.; Gusenleitner, Daniel; Keskin, Derin B.; Babadi, Mehrtash; Mohammad, Arman; Gnirke, Andreas; Clement, Kendell; Cartun, Zachary J.; Van Allen, Eliezer M.; Miao, Diana; Huang, Ying; Snyder, Alexandra; Merghoub, Taha; Wolchok, Jedd D.; Garraway, Levi A.; Meissner, Alexander; Weber, Jeffrey S.; Hacohen, Nir; Neuberg, Donna; Potts, Patrick R.; Murphy, George F.; Lian, Christine G.; Schadendorf, Dirk; Hodi, F. Stephen; Wu, Catherine J.
    Cancer-Germline Antigen Expression Discriminates Clinical Outcome to CTLA-4 Blockade
    In: Cell, Vol. 173, 2018, Nr. 3, pp. 624 – 633.e8
    DOI, Online Full Text (Open Access)
  • Dummer, Reinhard; Ascierto, Paolo A; Gogas, Helen J; Arance, Ana; Mandala, Mario; Liszkay, Gabriella; Garbe, Claus; Schadendorf, Dirk; Krajsova, Ivana; Gutzmer, Ralf; Chiarion-Sileni, Vanna; Dutriaux, Caroline; de Groot, Jan Willem B; Yamazaki, Naoya; Loquai, Carmen; Moutouh-de Parseval, Laure A; Pickard, Michael D; Sandor, Victor; Robert, Caroline; Flaherty, Keith T
    Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS) : a multicentre, open-label, randomised phase 3 trial
    In: The Lancet Oncology, Vol. 19, 2018, Nr. 5, pp. 603 – 615
    DOI (Open Access)
  • Dummer, Reinhard G.; Schadendorf, Dirk; Hauschild, Axel; Santinami, Mario; Atkinson, Victoria G.; Mandala, Mario; Chiarion Sileni, Vanna; Larkin, James M. G.; Nyakas, Marta S.; Dutriaux, Caroline; Haydon, Andrew M. M.; Mortier, Laurent; Robert, Caroline; Schachter, Jacob M.; Feng, X.; Jong, Egbert de; Mookerjee, Bijoyesh P.; Kefford, Rick F.; Kirkwood, John M.; Long, Georgina V.
    Estimate of long-term relapse-free survival (RFS) and analysis of baseline factors associated with RFS in the COMBI-AD trial
    In: Annals of Oncology, Vol. 29, 2018, Nr. Suppl. 8, pp. viii445
    DOI (Open Access)
  • Miao, Diana; Margolis, Claire A.; Vokes, Natalie I.; Liu, David; Taylor-Weiner, Amaro; Wankowicz, Stephanie M.; Adeegbe, Dennis; Keliher, Daniel; Schilling, Bastian; Tracy, Adam; Manos, Michael; Chau, Nicole G.; Hanna, Glenn J.; Polak, Paz; Rodig, Scott J.; Signoretti, Sabina; Sholl, Lynette M.; Engelman, Jeffrey A.; Getz, Gad; Jänne, Pasi A.; Haddad, Robert I.; Choueiri, Toni K.; Barbie, David A.; Haq, Rizwan; Awad, Mark M.; Schadendorf, Dirk; Hodi, F. Stephen; Bellmunt, Joaquim; Wong, Kwok-Kin; Hammerman, Peter; Van Allen, Eliezer M.
    Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors
    In: Nature Genetics, Vol. 50, 2018, Nr. 9, pp. 1271 – 1281
    DOI, Online Full Text (Open Access)
  • Hodi, Frank Stephen; Chiarion-Sileni, Vanna; Gonzalez, Rene; Grob, Jean-Jacques; Rutkowski, Piotr; Cowey, Charles Lance; Lao, Christopher D; Schadendorf, Dirk; Wagstaff, John; Dummer, Reinhard; Ferrucci, Pier Francesco; Smylie, Michael; Hill, Andrew; Hogg, David; Marquez-Rodas, Ivan; Jiang, Joel; Rizzo, Jasmine; Larkin, James; Wolchok, Jedd D
    Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067) : 4-year outcomes of a multicentre, randomised, phase 3 trial
    In: The Lancet Oncology, Vol. 19, 2018, Nr. 11, pp. 1480 – 1492
    DOI
  • Duffy, David L.; Zhu, Gu; Li, Xin; Sanna, Marianna; Iles, Mark M.; Jacobs, Leonie C.; Evans, David M.; Yazar, Seyhan; Beesley, Jonathan; Law, Matthew H.; Kraft, Peter; Visconti, Alessia; Taylor, John C.; Lui, Fan; Wright, Margaret J.; Henders, Anjali K.; Bowdler, Lisa; Glass, Dan; Ikram, Arfan M.; Uitterlinden, André G.; Madden, Pamela A.; Heath, Andrew C.; Nelson, Elliot C.; Green, Adele C.; Chanock, Stephen; Barrett, Jennifer H.; Brown, Matthew A.; Hayward, Nicholas K.; MacGregor, Stuart; Sturm, Richard A.; Hewitt, Alex W.; Lee, Jeffrey E.; Brossard, Myriam; Moses, Eric K.; Song, Fengju; Kumar, Rajiv; Easton, Douglas F.; Pharoah, Paul D. P.; Swerdlow, Anthony J.; Kypreou, Katerina P.; Harland, Mark; Randerson-Moor, Juliette; Akslen, Lars A.; Andresen, Per A.; Avril, Marie-Françoise; Azizi, Esther; Scarrà, Giovanna Bianchi; Brown, Kevin M.; Dębniak, Tadeusz; Elder, David E.; Fang, Shenying; Friedman, Eitan; Galan, Pilar; Ghiorzo, Paola; Gillanders, Elizabeth M.; Goldstein, Alisa M.; Gruis, Nelleke A.; Hansson, Johan; Helsing, Per; Hočevar, Marko; Höiom, Veronica; Ingvar, Christian; Kanetsky, Peter A.; Chen, Wei V.; Landi, Maria Teresa; Lang, Julie; Lathrop, G. Mark; Lubiński, Jan; Mackie, Rona M.; Mann, Graham J.; Molven, Anders; Novaković, Srdjan; Olsson, Håkan; Puig, Susana; Puig-Butille, Joan Anton; Radford-Smith, Graham L.; van der Stoep, Nienke; van Doorn, Remco; Whiteman, David C.; Craig, Jamie E.; Schadendorf, Dirk; Simms, Lisa A.; Burdon, Kathryn P.; Nyholt, Dale R.; Pooley, Karen A.; Orr, Nicholas; Stratigos, Alexander J.; Cust, Anne E.; Ward, Sarah V.; Schulze, Hans-Joachim; Dunning, Alison M.; Demenais, Florence; Amos, Christopher I.; Kayser, Manfred; Hunter, David J.; Newton Bishop, Julia A.; Spector, Timothy D.; Montgomery, Grant W.; Mackey, David A.; Smith, George Davey; Nijsten, Tamar E.; Bishop, D. Timothy; Bataille, Veronique; Falchi, Mario; Han, Jiali; Martin, Nicholas G.
    Novel pleiotropic risk loci for melanoma and nevus density implicate multiple biological pathways
    In: Nature Communications, Vol. 9, 2018, Nr. 1, pp. 4774
    DOI (Open Access)
  • Hodi, Frank S.; Chiarion-Sileni, Vanna; Gonzalez, René C.; Grob, Jean J.; Rutkowski, Piotr; Cowey, Charles L.; Lao, Christopher D.; Schadendorf, Dirk; Wagstaff, John; Dummer, Reinhard G.; Ferrucci, Pier F.; Smylie, Michael; Hill, A. G.; Hogg, David; Márquez-Rodas, Iván; Jiang, Joel; Rizzo, Jasmine I.; Larkin, James M. G.; Wolchok, J.
    Overall survival at 4 years of follow-up in a phase III trial of nivolumab plus ipilimumab combination therapy in advanced melanoma (CheckMate 067)
    In: Annals of Oncology, Vol. 29, 2018, Nr. Suppl. 8, pp. viii735
    DOI (Open Access)
  • Dummer, Reinhard; Ascierto, Paolo A.; Gogas, Helen J.; Arance, Ana; Mandala, Mario; Liszkay, Gabriella; Garbe, Claus; Schadendorf, Dirk; Krajsova, Ivana; Gutzmer, Ralf; Chiarion Sileni, Vanna; Dutriaux, Caroline; de Groot, Jan Willem B.; Yamazaki, Naoya; Loquai, Carmen; Moutouh-de Parseval, Laure A.; Pickard, Michael D.; Sandor, Victor; Robert, Caroline; Flaherty, Keith T.
    Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS) : A multicentre, open-label, randomised, phase 3 trial
    In: The Lancet Oncology, Vol. 19, 2018, Nr. 10, pp. 1315 – 1327
    DOI
  • Jockenhöfer, Finja; Schimming, Tobias T.; Schaller, Jörg; Moege, Jürgen; Livingstone, Elisabeth; Salva, Katrin A.; Zimmer, Lisa; Schadendorf, Dirk; Rösch, Alexander
    Sebaceous tumours: more than skin deep
    In: Gut, Vol. 67, 2018, Nr. 11, pp. 2045 – 2053
    DOI
  • Long, Georgina V.; Hauschild, Axel; Santinami, Mario; Atkinson, Victoria G.; Mandala, Mario; Chiarion-Sileni, Vanna; Larkin, James M. G.; Robert, Caroline; Schadendorf, Dirk; Dasgupta, Kohinoor; Shilkrut, Mark; Garrett, James; Brase, Jan C.; Kefford, Rick F.; Kirkwood, John M.; Dummer, Reinhard G.
    Updated relapse-free survival (RFS) and biomarker analysis in the COMBI-AD trial of adjuvant dabrafenib + trametinib (D + T) in patients (pts) with resected BRAF V600-mutant stage III melanoma
    In: Annals of Oncology, Vol. 29, 2018, Nr. Suppl. 8, pp. viii734 – viii735
    DOI (Open Access)
  • Schadendorf, Dirk; et.al.
    Updated relapse-free survival (RFS) and biomarker analysis in the COMBI-AD trial of adjuvant dabrafenib plus trametinib (D plus T) in patients (pts) with resected BRAF V600-mutant stage III melanoma
    In: Annals of Oncology, Vol. 29, 2018, Nr. Suppl. 8
  • Sucker, Antje; Zhao, Fang; Pieper, Natalia; Heeke, Christina; Maltaner, Raffaela; Stadtler, Nadine; Real, Birgit; Bielefeld, Nicola; Howe, Sebastian; Weide, Benjamin; Gutzmer, Ralf; Utikal, Jochen; Loquai, Carmen; Gogas, Helen; Klein-Hitpaß, Ludger; Zeschnigk, Michael; Westendorf, Astrid; Trilling, Mirko; Horn, Susanne; Schilling, Bastian; Schadendorf, Dirk; Griewank, Klaus; Paschen, Annette
    Acquired IFNγ 3 resistance impairs anti-Tumor immunity and gives rise to T-cell-resistant melanoma lesions
    In: Nature Communications, Vol. 8, 2017, 15440
    DOI (Open Access)
  • Dummer, Reinhard; Schadendorf, Dirk; Ascierto, Paolo A; Arance, Ana; Dutriaux, Caroline; Di Giacomo, Anna Maria; Rutkowski, Piotr; Del Vecchio, Michele; Gutzmer, Ralf; Mandala, Mario; Thomas, Luc; Demidov, Lev; Garbe, Claus; Hogg, David; Liszkay, Gabriella; Queirolo, Paola; Wasserman, Ernesto; Ford, James; Weill, Marine; Sirulnik, L Andres; Jehl, Valentine; Bozón, Viviana; Long, Georgina V; Flaherty, Keith
    Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO) : a multicentre, open-label, randomised, phase 3 trial
    In: The Lancet Oncology, Vol. 18, 2017, Nr. 4, pp. 435 – 445
    DOI
  • Long, G.V.; Flaherty, K.T.; Stroyakovskiy, D.; Gogas, H.; Levchenko, E.; de Braud, F.; Larkin, J.; Garbe, C.; Jouary, T.; Hauschild, A.; Chiarion-Sileni, V.; Lebbe, C.; Mandalà, M.; Millward, M.; Arance, A.; Bondarenko, I.; Haanen, J.B.A.G.; Hansson, J.; Utikal, J.; Ferraresi, V.; Mohr, P.; Probachai, V.; Schadendorf, Dirk; Nathan, P.; Robert, C.; Ribas, A.; Davies, M.A.; Lane, S.R.; Legos, J.J.; Mookerjee, B.; Grob, J-J
    Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma : long-term survival and safety analysis of a phase 3 study
    In: Annals of Oncology, Vol. 28, 2017, Nr. 7, pp. 1631 – 1639
    DOI (Open Access)
  • Guo, Jun; Carvajal, Richard D.; Dummer, Reinhard G.; Hauschild, Axel; Daud, Adil I.; Bastian, Boris C.; Markovic, Svetomir N.; Queirolo, Paola; Arance, Ana Maria; Berking, Carola; Camargo, Veridiana P.; Herchenhorn, Daniel; Petrella, Teresa M.; Schadendorf, Dirk; Sharfman, William H.; Testori, Alessandro; Novick, Steven C.; Hertle, Sabine; Nourry, C.; Chen, Q.; Hodi, Frank Stephen
    Efficacy and safety of nilotinib in patients with kit-mutated metastatic or inoperable melanoma : Final results from the global, single-arm, phase ii team trial
    In: Annals of Oncology, Vol. 28, 2017, Nr. 6, pp. 1380 – 1387
    DOI (Open Access)
  • Ascierto, Paolo A; Del Vecchio, Michele; Robert, Caroline; Mackiewicz, Andrzej; Chiarion-Sileni, Vanna; Arance, Ana; Lebbé, Céleste; Bastholt, Lars; Hamid, Omid; Rutkowski, Piotr; McNeil, Catriona; Garbe, Claus; Loquai, Carmen; Dreno, Brigitte; Thomas, Luc; Grob, Jean-Jacques; Liszkay, Gabriella; Nyakas, Marta; Gutzmer, Ralf; Pikiel, Joanna; Grange, Florent; Hoeller, Christoph; Ferraresi, Virginia; Smylie, Michael; Schadendorf, Dirk; Mortier, Laurent; Svane, Inge Marie; Hennicken, Delphine; Qureshi, Anila; Maio, Michele
    Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma : a randomised, double-blind, multicentre, phase 3 trial
    In: The Lancet Oncology, Vol. 18, 2017, Nr. 5, pp. 611 – 622
    DOI
  • Long, Georgina V.; Weber, Jeffrey S.; Larkin, James; Atkinson, Victoria; Grob, Jean-Jacques; Schadendorf, Dirk; Dummer, Reinhard; Robert, Caroline; Márquez-Rodas, Ivan; McNeil, Catriona; Schmidt, Henrik; Briscoe, Karen; Baurain, Jean-François; Hodi, F Stephen; Wolchok, Jedd D.
    Nivolumab for Patients With Advanced Melanoma Treated Beyond Progression : Analysis of 2 Phase 3 Clinical Trials
    In: JAMA Oncology, Vol. 3, 2017, Nr. 11, pp. 1511 – 1519
    DOI, Online Full Text (Open Access)
  • Jacquelot, N; Roberti, M P; Enot, D P; Rusakiewicz, S; Ternès, N; Jegou, S; Woods, D M; Sodré, A L; Hansen, M; Meirow, Y; Sade-Feldman, M; Burra, A; Kwek, S S; Flament, C; Messaoudene, M; Duong, C P M; Chen, L; Kwon, B S; Anderson, A C; Kuchroo, V K; Weide, B; Aubin, F; Borg, C; Dalle, S; Beatrix, O; Ayyoub, M; Balme, B; Tomasic, G; Di Giacomo, A M; Maio, M; Schadendorf, Dirk; Melero, I; Dréno, B; Khammari, A; Dummer, R; Levesque, M; Koguchi, Y; Fong, L; Lotem, M; Baniyash, M; Schmidt, H; Svane, I M; Kroemer, G; Marabelle, A; Michiels, S; Cavalcanti, A; Smyth, M J; Weber, J S; Eggermont, A M; Zitvogel, L
    Predictors of responses to immune checkpoint blockade in advanced melanoma
    In: Nature Communications, Vol. 8, 2017, pp. 592
    DOI (Open Access)
  • Kalkavan, Halime; Sharma, Piyush; Kasper, Stefan; Helfrich, Iris; Pandyra, Aleksandra A.; Gassa, Asmae; Virchow, Isabel; Flatz, Lukas; Brandenburg, Tim; Namineni, Sukumar; Heikenwalder, Mathias; Höchst, Bastian; Knolle, Percy A.; Wollmann, Guido; Von Laer, Dorothee; Drexler, Ingo; Rathbun, Jessica; Cannon, Paula M.; Scheu, Stefanie; Bauer, Jens; Chauhan, Jagat; Häussinger, Dieter; Willimsky, Gerald; Löhning, Max; Schadendorf, Dirk; Brandau, Sven; Schuler, Martin; Lang, Philipp A.; Lang, Karl S.
    Spatiotemporally restricted arenavirus replication induces immune surveillance and type i interferon-dependent tumour regression
    In: Nature Communications, Vol. 8, 2017, pp. 14447
    DOI (Open Access)
  • Dréno, Brigitte; Kunstfeld, Rainer; Hauschild, Axel; Fosko, Scott; Zloty, David; Labeille, Bruno; Grob, Jean-Jacques; Puig, Susana; Gilberg, Frank; Bergström, Daniel; Page, Damian R; Rogers, Gary; Schadendorf, Dirk
    Two intermittent vismodegib dosing regimens in patients with multiple basal-cell carcinomas (MIKIE) : a randomised, regimen-controlled, double-blind, phase 2 trial
    In: The Lancet Oncology, Vol. 18, 2017, Nr. 3, pp. 404 – 412
    DOI
  • McArthur, Grant A.; Maio, Michele; Arance, Ana Maria; Nathan, Paul D.; Blank, Christian U.; Avril, Marie Françoise; Garbe, Claus; Hauschild, Axel; Schadendorf, Dirk; Hamid, Omid A.; Fluck, Michael; Thebeau, Melissa S.; Schachter, Jacob M.; Kefford, Rick F.; Chamberlain, Marc Charles; Makrutzki, Martina; Robson, Susan; Gonzalez, René C.; Margolin, Kim A.
    Vemurafenib in metastatic melanoma patients with brain metastases : An open-label, single-arm, phase 2, multicentre study
    In: Annals of Oncology, Vol. 28, 2017, Nr. 3, pp. 634 – 641
    DOI
  • Campigotto, F.; Schadendorf, Dirk; Nägeli, M.; Micaletto, S.; Schmid, H.; Goldinger, S.M.; Kriemler-Krahn, U.; Dummer, R.; Michielin, O.A.; Pedroncelli, A.
    A phase I, open-label study of pasireotide in patients with BRAF- and NRAS-wild type, unresectable and or metastatic melanoma
    In: Annals of Oncology, Vol. 27, 2016, Nr. Suppl. 6
    DOI
  • Eigentler, T K; Gutzmer, R; Hauschild, A; Heinzerling, L; Schadendorf, Dirk; Nashan, D; Hölzle, E; Kiecker, F; Becker, Jürgen; Sunderkötter, C; Moll, I; Richtig, E; Pönitzsch, I; Pehamberger, H; Kaufmann, R; Pföhler, C; Vogt, T; Berking, C; Praxmarer, M; Garbe, C
    Adjuvant treatment with pegylated interferon ?-2a versus low-dose interferon ?-2a in patients with high-risk melanoma : a randomized phase III DeCOG trial
    In: Annals of Oncology, Vol. 27, 2016, Nr. 8, pp. 1625 – 1632
    DOI (Open Access)
  • Gebhardt, C.; Sucker, A.; Schadendorf, Dirk; Haselmann, V.H.; Neumaier, M.; Duda, A.; Brechtel, I.; Utikal, J.
    Analysis of BRAF V600E mutation status – concordance of results from circulating tumor DNA and tissue-based testing and impact on prediction of the clinical course in patients undergoing BRAFi therapy
    In: Annals of Oncology, Vol. 27, 2016, Nr. Suppl. 6, pp. 1145P
    DOI
  • Robert, C.; Schadendorf, Dirk; Long, G.V.; Stroyakovskiy, D.; Levchenko, E.; Chiarion-Sileni, V.; Flaherty, K.; Nathan, P.; Ribas, A.; Davies, M.; Zhang, J.; Chen, L.; Mookerjee, B.; Redhu, S.; Grob, J.J.
    Analysis of patient-reported outcomes by disease progression status in patients (pts) with BRAF V600–mutant metastatic melanoma in the COMBI-d and COMBI-v trials
    In: Annals of Oncology, Vol. 27, 2016, Nr. Suppl. 6, pp. 1140P
    DOI
  • Hauschild, Axel; Schadendorf, Dirk
    Checkpoint inhibitors : a new standard of care for advanced Merkel cell carcinoma?
    In: The Lancet Oncology, Vol. 17, 2016, Nr. 10, pp. 1337 – 1339
    DOI
  • Schadendorf, Dirk; Hauschild, A.; Fosko, S.; Zloty, D.; Labeille, B.; Grob, J.J.; Puig, S.; Makrutzki, M.; Templeton, I.; Rogers, G.; Dreno, B.; Kunstfeld, R.
    Evaluation of the pharmacokinetic (PK) profile of vismodegib (VISMO) in patients (pts) with multiple basal cell carcinomas (BCCs) across two intermittent treatment regimens in the MIKIE study
    In: Annals of Oncology, Vol. 27, 2016, Nr. Suppl. 6, pp. 1152P
    DOI
  • Long, Georgina V; Grob, Jean-Jacques; Nathan, Paul; Ribas, Antoni; Robert, Caroline; Schadendorf, Dirk; Lane, Stephen R; Mak, Carmen; Legenne, Philippe; Flaherty, Keith T; Davies, Michael A
    Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment : a pooled analysis of individual patient data from randomised trials
    In: The Lancet Oncology, Vol. 17, 2016, Nr. 12, pp. 1743 – 1754
    DOI
  • Hamid, O.; Puzanov, I.; Dummer, R.; Schachter, J.; Daud, A.; Schadendorf, Dirk; Blank, C.; Cranmer, L.D.; Robert, C.; Pavlick, A.C.; Gonzalez, R.; Hodi, F.S.; Ascierto, P.A.; Salama, A.; Margolin, K.A.; Gangadhar, T.C.; Wei, Z.; Ebbinghaus, S.W.; Ibrahim, N.; Ribas, A.
    Final overall survival for KEYNOTE-002 : pembrolizumab (pembro) versus investigator-choice chemotherapy (chemo) for ipilimumab (ipi)-refractory melanoma
    In: Annals of Oncology, Vol. 27, 2016, Nr. Suppl. 6, pp. 1107O
    DOI
  • Nathan, P.; Levchenko, E.; Davies, M.; Chiarion-Sileni, V.; Grob, J.J.; Long, G.V.; Schadendorf, Dirk; Robert, C.; Chen, L.; Mookerjee, B.; Redhu, S.; Zhang, J.; Ribas, A.; Stroyakovskiy, D.; Flaherty, K.
    Health-related quality-of-life (HRQOL) impact of dabrafenib (D) and trametinib (T) vs BRAF inhibitor (BRAFi) monotherapy by lactate dehydrogenase (LDH) in patients (pts) with BRAF V600–mutant melanoma
    In: Annals of Oncology, Vol. 27, 2016, Nr. Suppl. 6, pp. 1137P
    DOI
  • Wolchok, J.; Wagstaff, J.; Long, G.V.; Hodi, F.S.; Hassel, J.; Hoeller, C.; Larkin, J.; Ascierto, P.A.; Lebbe, C.; Haanen, J.B.A.G.; Schadendorf, Dirk; Hogg, D.; Horak, C.; Robert, C.; Dummer, R.; Sileni, V.; Pavlick, A.C.; Rutkowski, P.; Corrie, P.
    PD-L1 expression as a biomarker for nivolumab (NIVO) plus ipilimumab (IPI) and NIVO alone in advanced melanoma (MEL) : A pooled analysis
    In: Annals of Oncology, Vol. 27, 2016, Nr. Suppl. 6, pp. 1112PD
    DOI
  • Grob, J.J.; Schadendorf, Dirk; Mookerjee, B.; Flaherty, K.; Ribas, A.; Nathan, P.; Lane, S.; Robert, C.; Long, G.V.; Davies, M.; Legos, J.J.
    Pooled analysis of factors to predict durable clinical outcomes with combination dabrafenib (D) and trametinib (T) across registration trials
    In: Annals of Oncology, Vol. 27, 2016, Nr. Suppl. 6, pp. 1134P
    DOI
  • Robert, C.; Karaszewska, B.; Schachter, J.; Rutkowski, P.; Mackiewicz, A.; Stroyakovskiy, D.; Dummer, R.; Grange, F.; Mortier, L.; Chiarion-Sileni, V.; Drucis, K.; Krajsová, I.; Hauschild, A.; Mookerjee, B.; Legos, J.J.; Zhang, Y.; Lane, S.; Schadendorf, Dirk
    Three-year estimate of overall survival in COMBI-v, a randomized phase 3 study evaluating first-line dabrafenib (D) + trametinib (T) in patients (pts) with unresectable or metastatic BRAF V600E/K–mutant cutaneous melanoma
    In: Annals of Oncology, Vol. 27, 2016, Nr. Suppl. 6, pp. LBA40
    DOI
  • Kaur, Amanpreet; Schadendorf, Dirk; Schilling, Bastian; Lehrmann, Elin; Yin, Xiangfan; Tang, Hsin-Yao; Meeth, Katrina; Kossenkov, Andrew V.; Ferrucci, Luigi; McDonnell, Nazli B.; Morissette, Rachel; Valiga, Alexander A.; Cheng, Phil; O’Connell, Michael P.; Appleton, Jessica; Dang, Vanessa M.; Kugel, Curtis H.; Ndoye, Abibatou; Behera, Reeti; Marchbank, Katie; Webster, Marie R.
    sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance
    In: Nature, Vol. 532, 2016, Nr. 7598, pp. 250 – 254
    DOI, Online Full Text (Open Access)
  • Ugurel, Selma; Loquai, Carmen; Kähler, Katharina; Hassel, Jessica; Berking, Carola; Zimmer, Lisa; Haubitz, Imme; Satzger, Imke; Müller-Brenne, Tina; Mikhaimer, Nadia C.; Becker, Jürgen; Kilian, Katharina J.; Schadendorf, Dirk; Heinzerling, Lucie; Kaatz, Martin; Utikal, Jochen; Göppner, Daniela; Pföhler, Claudia; Pflugfelder, Annette; Mößner, Rotraut; Gutzmer, Ralf
    A multicenter DeCOG study on predictors of vemurafenib therapy outcome in melanoma : pretreatment impacts survival
    In: Annals of Oncology, Vol. 26, 2015, Nr. 3, pp. 573 – 582
    DOI (Open Access)
  • Grob, Jean Jacques; Amonkar, Mayur M; Karaszewska, Boguslawa; Schachter, Jacob; Dummer, Reinhard; Mackiewicz, Andrzej; Stroyakovskiy, Daniil; Drucis, Kamil; Grange, Florent; Chiarion-Sileni, Vanna; Rutkowski, Piotr; Lichinitser, Mikhail; Levchenko, Evgeny; Wolter, Pascal; Hauschild, Axel; Long, Georgina V; Nathan, Paul; Ribas, Antoni; Flaherty, Keith; Sun, Peng; Legos, Jeffrey J; McDowell, Diane Opatt; Mookerjee, Bijoyesh; Schadendorf, Dirk; Robert, Caroline
    Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v) : results of a phase 3, open-label, randomised trial
    In: The Lancet Oncology, Vol. 16, 2015, Nr. 13, pp. 1389 – 1398
    DOI
  • Grob, Jean Jacques; Long, Georgina V; Schadendorf, Dirk; Flaherty, Keith
    Disease kinetics for decision-making in advanced melanoma : a call for scenario-driven strategy trials
    In: The Lancet Oncology, Vol. 16, 2015, Nr. 13, pp. e522 – e526
    DOI
  • Lorigan, Paul; Ascierto, Paolo A; Dummer, Reinhard; Eggermont, Alexander M; Flaherty, Keith T; Garbe, Claus; Gogas, Helen; Hauschild, Axel; Kefford, Richard F; Kirkwood, John M; Larkin, James; Long, Georgina V; Maio, Michele; McArthur, Grant A; Ribas, Antoni; Robert, Caroline; Schadendorf, Dirk; Sondak, Vernon K; Wolchok, Jedd D; Hudson, Andrew M
    Expanded access programmes : patient interests versus clinical trial integrity
    In: The Lancet Oncology, Vol. 16, 2015, Nr. 1, pp. 15 – 17
    DOI
  • Law, Matthew H.; Bishop, D. Timothy; Lee, Jeffrey E.; Brossard, Myriam; Martin, Nicholas G.; Moses, Eric K.; Song, Fengju; Barrett, Jennifer H.; Kumar, Rajiv; Easton, Douglas F.; Pharoah, Paul D. P.; Swerdlow, Anthony J.; Kypreou, Katerina P.; Taylor, John C.; Harland, Mark; Randerson-Moor, Juliette; Akslen, Lars A.; Andresen, Per A.; Avril, Marie-Françoise; Azizi, Esther; Scarrà, Giovanna Bianchi; Brown, Kevin M.; Dębniak, Tadeusz; Duffy, David L.; Elder, David E.; Fang, Shenying; Friedman, Eitan; Galan, Pilar; Ghiorzo, Paola; Gillanders, Elizabeth M.; Goldstein, Alisa M.; Gruis, Nelleke A.; Hansson, Johan; Helsing, Per; Hočevar, Marko; Höiom, Veronica; Ingvar, Christian; Kanetsky, Peter A.; Chen, Wei V.; Landi, Maria Teresa; Lang, Julie; Lathrop, G. Mark; Lubiński, Jan; Mackie, Rona M.; Mann, Graham J.; Molven, Anders; Montgomery, Grant W.; Novaković, Srdjan; Olsson, Håkan; Puig, Susanne; Puig-Butille, Joan Anton; Qureshi, Abrar A.; Radford-Smith, Graham L.; van der Stoep, Nienke; van Doorn, Remco; Whiteman, David C.; Craig, Jamie E.; Schadendorf, Dirk; Simms, Lisa A.; Burdon, Kathryn P.; Nyholt, Dale R.; Pooley, Karen A.; Orr, Nick; Stratigos, Alexander J.; Cust, Anne E.; Ward, Sarah V.; Hayward, Nicholas K.; Han, Jiali; Schulze, Hans-Joachim; Dunning, Alison M.; Newton Bishop, Julia A.; Demenais, Florence; Amos, Christopher I.; MacGregor, Stuart; Iles, Mark M.
    Genome-wide meta-analysis identifies five new susceptibility loci for cutaneous malignant melanoma
    In: Nature Genetics, Vol. 47, 2015, Nr. 9, pp. 987 – 995
    DOI, Online Full Text (Open Access)
  • The Cancer Genome Atlas Network; Schadendorf, Dirk; Klode, Joachim
    Genomic Classification of Cutaneous Melanoma
    In: Cell, Vol. 161, 2015, Nr. 7, pp. 1681 – 1696
    DOI (Open Access)
  • Ribas, Antoni; Puzanov, Igor; Dummer, Reinhard; Schadendorf, Dirk; Hamid, Omid; Robert, Caroline; Hodi, F. Stephen; Schachter, Jacob; Pavlick, Anna C.; Lewis, Karl D.; Cranmer, Lee D.; Blank, Christian U.; O'Day, Steven J.; Ascierto, Paolo A.; Salama, April K. S.; Margolin, Kim A.; Loquai, Carmen; Eigentler, Thomas K.; Gangadhar, Tara C.; Carlino, Matteo S.; Agarwala, Sanjiv S.; Moschos, Stergios J.; Sosman, Jeffrey A.; Goldinger, Simone M.; Shapira-Frommer, Ronnie; Gonzalez, Rene; Kirkwood, John M.; Wolchok, Jedd D.; Eggermont, Alexander; Li, Xiaoyun Nicole; Zhou, Wei; Zernhelt, Adriane M.; Lis, Joy; Ebbinghaus, Scot; Kang, S. Peter; Daud, Adil
    Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002) : a randomised, controlled, phase 2 trial
    In: The Lancet Oncology, Vol. 16, 2015, Nr. 8, pp. 908 – 918
    DOI
  • Hecht, Markus; Zimmer, Lisa; Loquai, Carmen; Weishaupt, Carsten; Gutzmer, Ralf; Schuster, B.; Gleisner, S.; Schulze, Björn; Goldinger, S. M.; Berking, Carola; Forschner, Andrea; Clemens, P.; Grabenbauer, Gerhard; Müller-Brenne, Tina; Bauch, Julia; Eich, Hans T.; Grabbe, Stephan; Schadendorf, Dirk; Schuler, Gerold; Keikavoussi, Petra; Semrau, S.; Fietkau, Rainer; Distel, Luitpold V.; Heinzerling, Lucie
    Radiosensitization by BRAF inhibitor therapy-mechanism and frequency of toxicity in melanoma patients
    In: Annals of Oncology, Vol. 26, 2015, Nr. 6, pp. 1238 – 1244
    DOI (Open Access)
  • Schilling, Bastian; Sondermann, Wiebke; Griewank, Klaus; Livingstone, Elisabeth; Zimmer, Lisa; Hillen, Uwe; Schadendorf, Dirk
    Reply to the letters to the editor ‘Differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanoma’ by Diwakar et al.
    In: Annals of Oncology, Vol. 26, 2015, Nr. 1, pp. 250 – 251
    DOI
  • Schilling, Bastian; Sondermann, W.; Zhao, F.; Griewank, Klaus; Livingstone, Elisabeth; Sucker, A.; Zelba, H.; Weide, B.; Trefzer, U.; Wilhelm, T.; Loquai, C.; Berking, C.; Hassel, J.; Kähler, K. C.; Utikal, J.; Al~ghazal, P.; Gutzmer, R.; Goldinger, S. M.; Zimmer, Lisa; Paschen, Annette; Hillen, Uwe; Schadendorf, Dirk
    Differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanoma
    In: Annals of Oncology, Vol. 25, 2014, Nr. 3, pp. 747 – 753
    DOI
  • Schadendorf, Dirk; Amonkar, M. M.; Milhem, M.; Grotzinger, K.; Demidov, L. V.; Rutkowski, P.; Garbe, C.; Dummer, R.; Hassel, J. C.; Wolter, P.; Mohr, P.; Trefzer, U.; Lefeuvre-Plesse, C.; Rutten, A.; Steven, N.; Ullenhag, G.; Sherman, L.; Wu, F. S.; Patel, K.; Casey, M.; Robert, C.
    Functional and symptom impact of trametinib versus chemotherapy in BRAF V600E advanced or metastatic melanoma : Quality-of-life analyses of the METRIC study
    In: Annals of Oncology, Vol. 25, 2014, Nr. 3, pp. 700 – 706
    DOI
  • Leyvraz, S.; Piperno-Neumann, S.; Suciu, S.; Baurain, J. F.; Zdzienicki, M.; Testori, A.; Marshall, E.; Scheulen, Max Ernst; Jouary, T.; Negrier, S.; Vermorken, J. B.; Kaempgen, E.; Durando, X.; Schadendorf, Dirk; Gurunath, R. K.; Keilholz, U.
    Hepatic intra-arterial versus intravenous fotemustine in patients with liver metastases from uveal melanoma (EORTC 18021) : A multicentric randomized trial
    In: Annals of Oncology, Vol. 25, 2014, Nr. 3, pp. 742 – 746
    DOI
  • McArthur, Grant A; Chapman, Paul B; Robert, Caroline; Larkin, James; Haanen, John B; Dummer, Reinhard; Ribas, Antoni; Hogg, David; Hamid, Omid; Ascierto, Paolo A; Garbe, Claus; Testori, Alessandro; Maio, Michele; Lorigan, Paul; Lebbé, Celeste; Jouary, Thomas; Schadendorf, Dirk; O'Day, Stephen J; Kirkwood, John M; Eggermont, Alexander M; Dréno, Brigitte; Sosman, Jeffrey A; Flaherty, Keith T; Yin, Ming; Caro, Ivor; Cheng, Suzanne; Trunzer, Kerstin; Hauschild, Axel
    Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3) : extended follow-up of a phase 3, randomised, open-label study
    In: The Lancet Oncology, Vol. 15, 2014, Nr. 3, pp. 323 – 332
    DOI, Online Full Text (Open Access)
  • Flaherty, Keith T.; Hennig, Michael; Lee, Sandra J.; Ascierto, Paolo A.; Dummer, Reinhard; Eggermont, Alexander M. M.; Hauschild, Axel; Kefford, Richard; Kirkwood, John M.; Long, Georgina V.; Lorigan, Paul; Mackensen, Andreas; McArthur, Grant; O'Day, Steven; Patel, Poulam M.; Robert, Caroline; Schadendorf, Dirk
    Surrogate endpoints for overall survival in metastatic melanoma: A meta-analysis of randomised controlled trials
    In: The Lancet Oncology, Vol. 15, 2014, Nr. 3, pp. 297 – 304
    DOI
  • Bald, Tobias; Quast, Thomas; Landsberg, Jennifer; Rogava, Meri; Glodde, Nicole; Lopez-Ramos, Dorys; Kohlmeyer, Judith; Riesenberg, Stefanie; van den Boorn-Konijnenberg, Debby; Hömig-Hölzel, Cornelia; Reuten, Raphael; Schadow, Benjamin; Weighardt, Heike; Wenzel, Daniela; Helfrich, Iris; Schadendorf, Dirk; Bloch, Wilhelm; Bianchi, Marco E; Lugassy, Claire; Barnhill, Raymond L; Koch, Manuel; Fleischmann, Bernd K; Förster, Irmgard; Kastenmüller, Wolfgang; Kolanus, Waldemar; Hölzel, Michael; Gaffal, Evelyn; Tüting, Thomas
    Ultraviolet-radiation-induced inflammation promotes angiotropism and metastasis in melanoma
    In: Nature, Vol. 507, 2014, Nr. 7490, pp. 109 – 113
    DOI
  • Ascierto, Paolo A.; Schadendorf, Dirk; Berking, Carola; Agarwala, Sanjiv S.; van Herpen, Carla M.L.; Queirolo, Paola; Blank, Christian U.; Hauschild, Axel; Beck, J Thaddeus; St-Pierre, Annie; Niazi, Faiz; Wandel, Simon; Peters, Malte; Zubel, Angela; Dummer, Reinhard
    MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: A non-randomised, open-label phase 2 study
    In: The Lancet Oncology, Vol. 14, 2013, Nr. 3, pp. 249 – 256
    DOI
  • Robert, Caroline; Dummer, Reinhard; Gutzmer, Ralf; Lorigan, Paul; Kim, Kevin B.; Nyakas, Marta; Arance, Ana; Liszkay, Gabriella; Schadendorf, Dirk; Cantarini, Mireille; Spencer, Stuart; Middleton, Mark R.
    Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma : A phase 2 double-blind randomised study
    In: The Lancet Oncology, Vol. 14, 2013, Nr. 8, pp. 733 – 740
    DOI
  • Hodis, Eran; Watson, Ian R.; Kryukov, Gregory V.; Arold, Stefan T.; Imielinski, Marcin; Theurillat, Jean-Philippe; Nickerson, Elizabeth; Auclair, Daniel; Li, Liren; Place, Chelsea; Dicara, Daniel; Ramos, Alex H.; Lawrence, Michael S.; Cibulskis, Kristian; Sivachenko, Andrey; Voet, Douglas; Saksena, Gordon; Stransky, Nicolas; Onofrio, Robert C.; Winckler, Wendy; Ardlie, Kristin; Wagle, Nikhil; Wargo, Jennifer; Chong, Kelly; Morton, Donald L.; Stemke-Hale, Katherine; Chen, Guo; Noble, Michael; Meyerson, Matthew; Ladbury, John E.; Davies, Michael A.; Gershenwald, Jeffrey E.; Wagner, Stephan N.; Hoon, Dave S.B.; Schadendorf, Dirk; Lander, Eric S.; Gabriel, Stacey B.; Getz, Gad; Garraway, Levi A.; Chin, Lynda
    A Landscape of Driver Mutations in Melanoma
    In: Cell, Vol. 150, 2012, Nr. 2, pp. 251 – 263
    DOI
  • Schadendorf, Dirk; Vaubel, Julia Marianne; Livingstone, Elisabeth; Zimmer, Lisa
    Advances and perspectives in immunotherapy of melanoma
    In: Annals of Oncology, Vol. 23, 2012, Nr. Suppl. 10, pp. x104 – x108
    DOI, Online Full Text
  • Long, Georgina V.; Trefzer, Uwe; Davies, Michael A.; Kefford, Richard F.; Ascierto, Paolo A.; Chapman, Paul B.; Puzanov, Igor; Hauschild, Axel; Robert, Caroline; Algazi, Alain; Mortier, Laurent; Tawbi, Hussein; Wilhelm, Tabea; Zimmer, Lisa; Switzky, Julie; Swann, Suzanne; Martin, Anne-Marie; Guckert, Mary; Goodman, Vicki; Streit, Michael; Kirkwood, John M.; Schadendorf, Dirk
    Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB) : A multicentre, open-label, phase 2 trial
    In: The Lancet Oncology, Vol. 13, 2012, Nr. 11, pp. 1087 – 1095
    DOI
  • Berger, Michael F.; Hodis, Eran; Heffernan, Timothy P.; Deribe, Yonathan Lissanu; Lawrence, Michael S.; Protopopov, Alexei; Ivanova, Elena; Watson, Ian R.; Nickerson, Elizabeth; Ghosh, Papia; Zhang, Hailei; Zeid, Rhamy; Ren, Xiaojia; Cibulskis, Kristian; Sivachenko, Andrey Y.; Wagle, Nikhil; Sucker, Antje; Sougnez, Carrie; Onofrio, Robert; Ambrogio, Lauren; Auclair, Daniel; Fennell, Timothy; Carter, Scott L.; Drier, Yotam; Stojanov, Petar; Singer, Meredith A.; Voet, Douglas; Jing, Rui; Saksena, Gordon; Barretina, Jordi; Ramos, Alex H.; Pugh, Trevor J.; Stransky, Nicolas; Parkin, Melissa; Winckler, Wendy; Mahan, Scott; Ardlie, Kristin; Baldwin, Jennifer; Wargo, Jennifer; Schadendorf, Dirk; Meyerson, Matthew; Gabriel, Stacey B.; Golub, Todd R.; Wagner, Stephan N.; Lander, Eric S.; Getz, Gad; Chin, Lynda; Garraway, Levi A.
    Melanoma genome sequencing reveals frequent PREX2 mutations
    In: Nature, Vol. 485, 2012, Nr. 7399, pp. 502 – 506
    DOI
  • Egberts, F.; Gutzmer, R.; Ugurel, Selma; Becker, J.C.; Trefzer, U.; Degen, A.; Schenck, F.; Frey, L.; Wilhelm, T.; Hassel, J.C.; Schadendorf, Dirk; Livingstone, Elisabeth; Mauch, C.; Garbe, C.; Berking, C.; Rass, K.; Mohr, P.; Kaehler, K.C.; Weichenthal, M.; Hauschild, A.
    Sorafenib and pegylated interferon-α2b in advanced metastatic melanoma : A multicenter phase II DeCOG trial
    In: Annals of Oncology, Vol. 22, 2011, Nr. 7, pp. 1667 – 1674
    DOI
  • Wolchok, J. D.; Neyns, B.; Linette, G.; Negrier, S.; Lutzky, J.; Thomas, L.; Waterfield, W.; Schadendorf, Dirk; Smylie, M.; Guthrie, T.; Grob, J. J.; Chesney, J.; Chin, K.; Chen, K.; Hoos, A.; O'Day, S. J.; Lebbé, C.
    Ipilimumab monotherapy in patients with pretreated advanced melanoma : a randomised, double-blind, multicentre, phase 2, dose-ranging study
    In: The Lancet Oncology, Vol. 11, 2010, Nr. 2, pp. 155 – 164
    DOI